Research Topics — Basic / Pre-Clinical ~ Miscellaneous Topics
~ Genetics of Breast & Ovarian Cancer

Includes references primarily of a basic research or pre-clinical nature—with little or no current clinical application—but can serve in looking forward to possible directions for HBOC topics.

List was last updated on Oct 13, 2019 @ 8:43 pm.


    • Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
    • Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.
    • J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]
    • Synergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G2 DNA damage checkpoint.
    • Mak JPY, Ma HT, Poon RYC.
    • Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0474.2019. doi: 10.1158/1535-7163.MCT-19-0474. [Epub ahead of print]
    • Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
    • Sawczuk B, Maciejczyk M, Sawczuk-Siemieniuk M, Posmyk R, Zalewska A, Car H.
    • Cancers (Basel). 2019 Oct 8;11(10). pii: E1501. doi: 10.3390/cancers11101501.
    • DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    • Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV.
    • Proc Natl Acad Sci U S A. 2019 Oct 7. pii: 201903765. doi: 10.1073/pnas.1903765116. [Epub ahead of print]
    • Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.
    • Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG.
    • Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0256.2019. doi: 10.1158/1535-7163.MCT-17-0256. [Epub ahead of print]
    • Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer.
    • Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S.
    • Nutr Cancer. 2019 Oct 1:1-10. doi: 10.1080/01635581.2019.1670216. [Epub ahead of print]
    • The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers.
    • Ismael M, Webb R, Ajaz M, Kirkby KJ, Coley HM.
    • Cancers (Basel). 2019 Sep 25;11(10). pii: E1429. doi: 10.3390/cancers11101429.
    • ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
    • Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    • Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0242.2019. doi: 10.1158/1535-7163.MCT-19-0242. [Epub ahead of print]
    • Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2-deficient cancer cells.
    • Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, A T M van Vugt M.
    • Mol Oncol. 2019 Sep 17. doi: 10.1002/1878-0261.12573. [Epub ahead of print]
    • BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells.
    • Luca P, Carmen M, Angela DS, Annamaria B, Erica S.
    • Genes (Basel). 2019 Sep 10;10(9). pii: E697. doi: 10.3390/genes10090697.
    • Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    • Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K.
    • Breast Cancer Res. 2019 Sep 6;21(1):104. doi: 10.1186/s13058-019-1192-2.
    • A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    • Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P.
    • Sci Rep. 2019 Aug 29;9(1):12511. doi: 10.1038/s41598-019-48929-0.
    • IMMUNODETECTION AND QUANTIFICATION OF ENZYMATIC MARKERS IN THECA CELLS: THE EARLY PROCESS OF OVARIAN STEROIDOGENESIS.
    • Asiabi P, Leonel ECR, Marbaix E, Dolmans MM, Amorim CA.
    • Biol Reprod. 2019 Aug 28. pii: ioz167. doi: 10.1093/biolre/ioz167. [Epub ahead of print]
    • DNA Damage and Hormone Related Cancer: a repair pathway view.
    • Pooley KA, Dunning AM.
    • Hum Mol Genet. 2019 Aug 22. pii: ddz206. doi: 10.1093/hmg/ddz206. [Epub ahead of print]
    • Review
    • EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.
    • Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B.
    • Nanomedicine (Lond). 2019 Aug 21. doi: 10.2217/nnm-2019-0132. [Epub ahead of print]
    • Chromatin Remodeling in Response to BRCA2-Crisis.
    • Gruber JJ, Chen J, Geller B, Jäger N, Lipchik AM, Wang G, Kurian AW, Ford JM, Snyder MP.
    • Cell Rep. 2019 Aug 20;28(8):2182-2193.e6. doi: 10.1016/j.celrep.2019.07.057.
    • Non-homologous end joining is more important than proton linear energy transfer in dictating cell death.
    • Bright SJ, Flint DB, Chakraborty S, McFadden CH, Yoon DS, Bronk L, Titt U, Mohan R, Grosshans DR, Sumazin P, Shaitelman SF, Asaithamby A, Sawakuchi GO.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 16. pii: S0360-3016(19)33645-4. doi: 10.1016/j.ijrobp.2019.08.011. [Epub ahead of print]
    • Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
    • Boraei ATA, Singh PK, Sechi M, Satta S.
    • Eur J Med Chem. 2019 Aug 14;182:111621. doi: 10.1016/j.ejmech.2019.111621. [Epub ahead of print]
    • A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
    • Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT.
    • Theranostics. 2019 Aug 14;9(21):6224-6238. doi: 10.7150/thno.36281. eCollection 2019.
    • The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.
    • Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]
    • The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    • Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0448.2019. doi: 10.1158/1078-0432.CCR-19-0448. [Epub ahead of print]
    • BRCA1 regulates HMGA2 levels in the Swan71 trophoblast cell line.
    • West RC, Russ JE, Bouma GJ, Winger QA.
    • Mol Reprod Dev. 2019 Aug 13. doi: 10.1002/mrd.23255. [Epub ahead of print]
    • Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    • Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, Terry MB, Teitelbaum SL, Neugut AI, Santella RM, Chen J, Gammon MD.
    • Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364. [Epub ahead of print]
    • BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work.
    • Bracci M, Ciarapica V, Zabaleta ME, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L.
    • Cancers (Basel). 2019 Aug 9;11(8). pii: E1146. doi: 10.3390/cancers11081146.
    • MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
    • Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R.
    • Proc Natl Acad Sci U S A. 2019 Aug 8. pii: 201903150. doi: 10.1073/pnas.1903150116. [Epub ahead of print]
    • Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
    • Zhong Y, Meng Y, Xu X, Zhao L, Li Z, You Q, Bian J.
    • Bioorg Chem. 2019 Aug 3;91:103181. doi: 10.1016/j.bioorg.2019.103181. [Epub ahead of print]
    • Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
    • Zhang H, Yu N, Chen Y, Yan K, Wang X.
    • J Cell Biochem. 2019 Aug;120(8):13037-13045. doi: 10.1002/jcb.28574. Epub 2019 Mar 14.
    • Emerging Roles of RAD52 in Genome Maintenance.
    • Jalan M, Olsen KS, Powell SN.
    • Cancers (Basel). 2019 Jul 23;11(7). pii: E1038. doi: 10.3390/cancers11071038.
    • Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
    • Basree MM, Shinde N, Koivisto C, Cuitino M, Kladney R, Zhang J, Stephens J, Palettas M, Zhang A, Kim HK, Acero-Bedoya S, Trimboli A, Stover DG, Ludwig T, Ganju R, Weng D, Shields P, Freudenheim J, Leone GW, Sizemore GM, Majumder S, Ramaswamy B.
    • Breast Cancer Res. 2019 Jul 17;21(1):80. doi: 10.1186/s13058-019-1163-7.
    • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    • Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.
    • J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.
    • How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
    • Venkitaraman AR.
    • DNA Repair (Amst). 2019 Jul 8:102668. doi: 10.1016/j.dnarep.2019.102668. [Epub ahead of print]
    • Review
    • Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
    • Sargazi S, Saravani R, Zavar Reza J, Jaliani HZ, Mirinejad S, Rezaei Z, Zarei S.
    • EXCLI J. 2019 Jul 8;18:485-498. doi: 10.17179/excli2019-1098. eCollection 2019.
    • 6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner.
    • Laera L, Guaragnella N, Giannattasio S, Moro L.
    • Cancers (Basel). 2019 Jul 5;11(7). pii: E945. doi: 10.3390/cancers11070945.
    • BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
    • Kim H, Lin Q, Yun Z.
    • Sci Rep. 2019 Jul 4;9(1):9702. doi: 10.1038/s41598-019-46210-y.
    • Isomerization of BRCA1-BARD1 promotes replication fork protection.
    • Daza-Martin M, Starowicz K, Jamshad M, Tye S, Ronson GE, MacKay HL, Chauhan AS, Walker AK, Stone HR, Beesley JFJ, Coles JL, Garvin AJ, Stewart GS, McCorvie TJ, Zhang X, Densham RM, Morris JR.
    • Nature. 2019 Jul 3. doi: 10.1038/s41586-019-1363-4. [Epub ahead of print]
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.
    • Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
    • Kundur S, Prayag A, Selvakumar P, Nguyen H, McKee L, Cruz C, Srinivasan A, Shoyele S, Lakshmikuttyamma A.
    • J Cell Physiol. 2019 Jul;234(7):11103-11118. doi: 10.1002/jcp.27761. Epub 2018 Nov 27.
    • How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.
    • Swiatnicki MR, Andrechek ER.
    • J Mammary Gland Biol Neoplasia. 2019 Jun 21. doi: 10.1007/s10911-019-09433-3. [Epub ahead of print]
    • Review
    • BRCA2 deficiency is a potential driver for human primary ovarian insufficiency.
    • Miao Y, Wang P, Xie B, Yang M, Li S, Cui Z, Fan Y, Li M, Xiong B.
    • Cell Death Dis. 2019 Jun 17;10(7):474. doi: 10.1038/s41419-019-1720-0.
    • A Mechanistic Approach to understand the Allosteric Reverse Signaling by Selective and Trapping Poly(ADP-ribose) Polymerase 1 (PARP-1) Inhibitors.
    • Kumar C, Lakshmi PTV, Arunachalam A.
    • J Biomol Struct Dyn. 2019 Jun 16:1-12. doi: 10.1080/07391102.2019.1633406. [Epub ahead of print]
    • Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
    • Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL.
    • Clin Cancer Res. 2019 Jun 13. doi: 10.1158/1078-0432.CCR-18-4222. [Epub ahead of print]
    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
    • Lal A, Ramazzotti D, Weng Z, Liu K, Ford JM, Sidow A.
    • BMC Med Genomics. 2019 Jun 10;12(1):84. doi: 10.1186/s12920-019-0545-0.
    • Clinical Impact of RANK Signalling in Ovarian Cancer.
    • Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.
    • Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.
    • Discovery of naphthacemycins as a novel class of PARP1 inhibitors.
    • Shen W, Lu X, Zhu J, Mu Y, Xu Y, Gao J, Zhang X, Zheng Z.
    • Bioorg Med Chem Lett. 2019 May 28. pii: S0960-894X(19)30361-0. doi: 10.1016/j.bmcl.2019.05.055. [Epub ahead of print]
    • BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    • Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K.
    • Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    • Shen YT, Wang L, Evans JC, Allen C, Piquette-Miller M.
    • Int J Mol Sci. 2019 May 21;20(10). pii: E2498. doi: 10.3390/ijms20102498.
    • Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells.
    • Sargazi S, Saravani R, Zavar Reza J, Zarei Jaliani H, Galavi H, Liliya Viacheslavovna M, Abtahi NA.
    • Iran Biomed J. 2019 May 18. [Epub ahead of print]
    • BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
    • Hilton HN, Patterson McDonald LJ, Santucci N, van der Bent FR, Silvestri A, Graham JD, Clarke CL.
    • J Mammary Gland Biol Neoplasia. 2019 May 18. doi: 10.1007/s10911-019-09431-5. [Epub ahead of print]
    • Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
    • Wang F, Zhu S, Fisher LA, Wang L, Eurek NJ, Wahl JK 3rd, Lan L, Peng A.
    • Cancer Res. 2019 May 15;79(10):2526-2535. doi: 10.1158/0008-5472.CAN-18-1673. Epub 2019 Feb 7.
    • Commentary
    • Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
    • Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM.
    • Sci Transl Med. 2019 May 15;11(492). pii: eaav4508. doi: 10.1126/scitranslmed.aav4508.

    Research news:

    Mechanism of Cediranib/Olaparib Combo Revealed.

    • Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
    • Eskilera GG, Cecener G, Dikmen G, Egeli U, Tunca B.
    • Curr Drug Deliv. 2019 May 14. doi: 10.2174/1567201816666190515105532. [Epub ahead of print]
    • Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
    • Baldwin P, Ohman AW, Medina JE, McCarthy ET, Dinulescu DM, Sridhar S.
    • Front Oncol. 2019 May 10;9:353. doi: 10.3389/fonc.2019.00353. eCollection 2019.
    • Veliparib: a new therapeutic option in ovarian cancer?
    • Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G.
    • Future Oncol. 2019 May 10. doi: 10.2217/fon-2018-0883. [Epub ahead of print]
    • Review
    • Associating expression and genomic data using co-occurrence measures.
    • Larmuseau M, Verbeke LPC, Marchal K.
    • Biol Direct. 2019 May 9;14(1):10. doi: 10.1186/s13062-019-0240-2.
    • The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone.
    • Macciò A, Madeddu C.
    • Int J Cancer. 2019 May 9. doi: 10.1002/ijc.32392. [Epub ahead of print]
    • Letter
    • WIP1 Contributes to the Adaptation of Fanconi Anemia Cells to DNA Damage as Determined by the Regulatory Network of the Fanconi Anemia and Checkpoint Recovery Pathways.
    • Rodríguez A, Naveja JJ, Torres L, García de Teresa B, Juárez-Figueroa U, Ayala-Zambrano C, Azpeitia E, Mendoza L, Frías S.
    • Front Genet. 2019 May 3;10:411. doi: 10.3389/fgene.2019.00411. eCollection 2019.
    • Design and Synthesis of Poly(ADP-ribose) polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
    • Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT.
    • J Med Chem. 2019 May 1. doi: 10.1021/acs.jmedchem.8b01709. [Epub ahead of print]
    • BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
    • Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    • Wen WX, Leong CO.
    • PLoS One. 2019 Apr 25;14(4):e0215381. doi: 10.1371/journal.pone.0215381. eCollection 2019.
    • DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    • Shi Y, Jin J, Wang X, Ji W, Guan X.
    • Neoplasia. 2019 Apr 24;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. [Epub ahead of print]
    • Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
    • Nhukeaw T, Hongthong K, Dyson PJ, Ratanaphan A.
    • Apoptosis. 2019 Apr 23. doi: 10.1007/s10495-019-01544-w. [Epub ahead of print]
    • PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.
    • Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.
    • Cancer Discov. 2019 Apr 23. pii: CD-18-1218. doi: 10.1158/2159-8290.CD-18-1218. [Epub ahead of print]
    • Fluorescent C-NanoDots for rapid detection of BRCA1, CFTR and MRP3 gene mutations.
    • García-Mendiola T, Elosegui CG, Bravo I, Pariente F, Jacobo-Martin A, Navio C, Rodriguez I, Wannemacher R, Lorenzo E.
    • Mikrochim Acta. 2019 Apr 23;186(5):293. doi: 10.1007/s00604-019-3386-9.
    • Dual TGFβ/BMP pathway inhibition enables expansion and characterization of multiple epithelial cell types of the normal and cancerous breast.
    • Prasad M, Kumar B, Bhat-Nakshatri P, Anjanappa M, Sandusky G, Miller KD, Storniolo AM, Nakshatri H.
    • Mol Cancer Res. 2019 Apr 16. pii: molcanres.0165.2019. doi: 10.1158/1541-7786.MCR-19-0165. [Epub ahead of print]
    • Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    • Ma X, Dang C, Min W, Diao Y, Hui W, Wang X, Dai Z, Wang X, Kang H.
    • Breast Cancer Res Treat. 2019 Apr 15. doi: 10.1007/s10549-019-05189-w. [Epub ahead of print]
    • MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
    • Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.
    • Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259. Epub 2019 Mar 1.
    • Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
    • Na B, Yu X, Withers T, Gilleran J, Yao M, Foo TK, Chen C, Moore D, Lin Y, Kimball SD, Xia B, Ganesan S, Carpizo DR.
    • NPJ Breast Cancer. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1. eCollection 2019.
    • BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    • Gorodetska I, Lukiyanchuk V, Peitzsch C, Kozeretska I, Dubrovska A.
    • Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32323. [Epub ahead of print]
    • N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance.
    • Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.
    • Cancer Res. 2019 Apr 9. pii: canres.3592.2018. doi: 10.1158/0008-5472.CAN-18-3592. [Epub ahead of print]
    • β-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    • Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.
    • Carcinogenesis. 2019 Apr 9. pii: bgz070. doi: 10.1093/carcin/bgz070. [Epub ahead of print]
    • Beyond Trophic Factors: Exploiting the Intrinsic Regenerative Properties of Adult Neurons.
    • Duraikannu A, Krishnan A, Chandrasekhar A, Zochodne DW.
    • Front Cell Neurosci. 2019 Apr 5;13:128. doi: 10.3389/fncel.2019.00128. eCollection 2019.
    • Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
    • Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ.
    • Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.
    • Dissecting PARP inhibitor resistance with functional genomics.
    • Pettitt SJ, Lord CJ.
    • Curr Opin Genet Dev. 2019 Apr 4;54:55-63. doi: 10.1016/j.gde.2019.03.001. [Epub ahead of print]
    • Overexpression of BRCA1 in Neural Stem Cells Enhances Cell Survival and Functional Recovery after Transplantation into Experimental Ischemic Stroke.
    • Xu P, Shi X, Zhang X, Liu Q, Xie Y, Hong Y, Li J, Peng M, Liu X, Xu G.
    • Oxid Med Cell Longev. 2019 Apr 3;2019:8739730. doi: 10.1155/2019/8739730. eCollection 2019.
    • Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    • Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ.
    • Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
    • 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    • Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM, Shen K, Wang L.
    • Breast Cancer Res Treat. 2019 Apr 1. doi: 10.1007/s10549-019-05194-z. [Epub ahead of print]
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    • Button B, Croessmann S, Chu D, Rosen DM, Zabransky DJ, Dalton WB, Cravero K, Kyker-Snowman K, Waters I, Karthikeyan S, Christenson ES, Donaldson J, Hunter T, Dennison L, Ramin C, May B, Roden R, Petry D, Armstrong DK, Visvanathan K, Park BH.
    • Breast Cancer Res Treat. 2019 Apr;174(2):401-412. doi: 10.1007/s10549-018-05087-7. Epub 2018 Dec 17.
    • RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination.
    • Baldock RA, Pressimone CA, Baird JM, Khodakov A, Luong TT, Grundy MK, Smith CM, Karpenshif Y, Bratton-Palmer DS, Prakash R, Jasin M, Garcin EB, Gon S, Modesti M, Bernstein KA.
    • DNA Repair (Amst). 2019 Apr;76:99-107. doi: 10.1016/j.dnarep.2019.02.008. Epub 2019 Feb 23.
    • 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    • Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.
    • Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.
    • The SuprMam1 breast cancer susceptibility locus disrupts the vitamin D/ calcium/ parathyroid hormone pathway and alters bone structure in congenic mice.
    • Ratnadiwakara M, Rooke M, Ohms SJ, French HJ, Williams RBH, Li RW, Zhang D, Lucas RM, Blackburn AC.
    • J Steroid Biochem Mol Biol. 2019 Apr;188:48-58. doi: 10.1016/j.jsbmb.2018.12.004. Epub 2018 Dec 7.
    • GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition.
    • Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.
    • Mol Cancer Ther. 2019 Mar 29. pii: molcanther.0770.2018. doi: 10.1158/1535-7163.MCT-18-0770. [Epub ahead of print]
    • The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.
    • Zhao W, Wiese C, Kwon Y, Hromas R, Sung P.
    • Annu Rev Biochem. 2019 Mar 27. doi: 10.1146/annurev-biochem-013118-111058. [Epub ahead of print]
    • Review
    • Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer.
    • Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJ, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.
    • Clin Cancer Res. 2019 Mar 26. pii: clincanres.0468.2018. doi: 10.1158/1078-0432.CCR-18-0468. [Epub ahead of print]
    • Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
    • Wu J, Mamidi TKK, Zhang L, Hicks C.
    • Int J Environ Res Public Health. 2019 Mar 23;16(6). pii: E1055. doi: 10.3390/ijerph16061055.
    • BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
    • Zong D, Adam S, Wang Y, Sasanuma H, Callén E, Murga M, Day A, Kruhlak MJ, Wong N, Munro M, Ray Chaudhuri A, Karim B, Xia B, Takeda S, Johnson N, Durocher D, Nussenzweig A.
    • Mol Cell. 2019 Mar 21;73(6):1267-1281.e7. doi: 10.1016/j.molcel.2018.12.010. Epub 2019 Jan 28.

    Research news:

    Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.

    • Polo-like Kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction.
    • Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G.
    • Clin Cancer Res. 2019 Mar 19. pii: clincanres.3516.2018. doi: 10.1158/1078-0432.CCR-18-3516. [Epub ahead of print]
    • DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    • Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.
    • Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
    • DNA polymerase θ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
    • Wang Z, Song Y, Li S, Kurian S, Xiang R, Chiba T, Wu X.
    • J Biol Chem. 2019 Mar 15;294(11):3909-3919. doi: 10.1074/jbc.RA118.005188. Epub 2019 Jan 17.
    • The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
    • Peng Y, Liao Q, Tan W, Peng C, Hu Z, Chen Y, Li Z, Li J, Zhen B, Zhu W, Li X, Yao Y, Song Q, Liu C, Qi X, He F, Pei H.
    • Nat Commun. 2019 Mar 15;10(1):1224. doi: 10.1038/s41467-019-09232-8.

    Press: New Biomarker Could Expand Effective PARP Inhibitor Treatment Options. (Clinical OMICs)

    • Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
    • Wilson A, Menon V, Khan Z, Alam A, Litovchick L, Yakovlev V.
    • Redox Biol. 2019 Mar 15;24:101169. doi: 10.1016/j.redox.2019.101169. [Epub ahead of print]
    • The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition.
    • Alqahtani S, Welton K, Gius JP, Elmegerhi S, Kato TA.
    • Int J Mol Sci. 2019 Mar 14;20(6). pii: E1274. doi: 10.3390/ijms20061274.
    • Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
    • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.
    • Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
    • Ottria R, Ravelli A, Miceli M, Casati S, Orioli M, Ciuffreda P.
    • Molecules. 2019 Mar 11;24(5). pii: E989. doi: 10.3390/molecules24050989.
    • Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
    • Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, D'Andrea AD, Elledge SJ.
    • Mol Cell. 2019 Mar 7;73(5):885-899.e6. doi: 10.1016/j.molcel.2018.12.008. Epub 2019 Jan 24.
    • Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
    • Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC.
    • Am J Cancer Res. 2019 Mar 1;9(3):608-618. eCollection 2019.
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
    • Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, In Chan U, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX.
    • Hum Mol Genet. 2019 Mar 1;28(5):842-857. doi: 10.1093/hmg/ddy398.
    • The Fanconi Anemia Pathway in Cancer.
    • Niraj J, Färkkilä A, D'Andrea AD.
    • Annu Rev Cancer Biol. 2019 Mar;3:457-478. doi: 10.1146/annurev-cancerbio-030617-050422. Epub 2018 Dec 3.
    • Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    • Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.
    • Cancer Sci. 2019 Mar;110(3):1064-1075. doi: 10.1111/cas.13947. Epub 2019 Feb 19.
    • Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers.
    • Turhan A, Foudi A, Hwang JW, Desterke C, Griscelli F, Bennaceur-Griscelli A.
    • Exp Hematol. 2019 Mar;71:61-67. doi: 10.1016/j.exphem.2019.01.003. Epub 2019 Jan 16.
    • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    • Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.
    • Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.
    • Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.
    • Wang Y, Niu H, Hu Z, Zhu M, Wang L, Han L, Qian L, Tian K, Yuan H, Lou H.
    • J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18.
    • CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
    • Zhao R, Kaakati R, Liu X, Xu L, Lee AK, Bachelder R, Li CY, Hollenbeck ST.
    • Plast Reconstr Surg. 2019 Mar;143(3):747-756. doi: 10.1097/PRS.0000000000005316.

    Research news:

    Discussion: CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.

    • Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    • Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.
    • Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.
    • Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly.
    • Tervasmäki A, Mantere T, Eshraghi L, Laurila N, Tuppurainen H, Ronkainen VP, Koivuluoma S, Devarajan R, Peltoketo H, Pylkäs K.
    • Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32234. [Epub ahead of print]
    • AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    • Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C.
    • Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613. doi: 10.1073/pnas.1815126116. Epub 2019 Feb 7.
    • Genetic variation and radiation quality impact cancer promoting cellular phenotypes in response to HZE exposure.
    • Sridharan DM, Enerio S, Wang C, LaBarge MA, Stampfer MR, Pluth JM.
    • Life Sci Space Res (Amst). 2019 Feb;20:101-112. doi: 10.1016/j.lssr.2018.10.002. Epub 2018 Oct 21.
    • Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    • Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J.
    • Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.
    • Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
    • Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N.
    • Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x.
    • Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells.
    • Lattimore VL, Pearson JF, Morley-Bunker AE, Investigators K, Spurdle AB, Robinson BA, Currie MJ, Walker LC.
    • Int J Mol Sci. 2019 Feb 6;20(3). pii: E693. doi: 10.3390/ijms20030693.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers.
    • Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A.
    • Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
    • A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
    • Hollern DP, Contreras CM, Dance-Barnes S, Silva GO, Pfefferle AD, Xiong J, Darr DB, Usary J, Mott KR, Perou CM.
    • Breast Cancer Res Treat. 2019 Feb;174(1):143-155. doi: 10.1007/s10549-018-5061-y. Epub 2018 Nov 27.
    • The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    • Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP.
    • Gynecol Oncol. 2019 Feb;152(2):426-433. doi: 10.1016/j.ygyno.2018.11.033. Epub 2018 Nov 30.
    • Review
    • Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
    • Tarpey MD, Valencia AP, Jackson KC, Amorese AJ, Balestrieri NP, Renegar RH, Pratt SJP, Ryan TE, McClung JM1,, Lovering RM, Spangenburg EE.
    • J Physiol. 2019 Feb;597(3):869-887. doi: 10.1113/JP276863. Epub 2018 Dec 16.
    • PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
    • Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.
    • Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14.
    • PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    • Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, Rueda BR.
    • Mol Cancer Res. 2019 Feb;17(2):431-445. doi: 10.1158/1541-7786.MCR-18-0594. Epub 2018 Nov 6.
    • CHK2-mediated regulation of PARP1 in oxidative DNA damage response.
    • Hsu PC, Gopinath RK, Hsueh YA, Shieh SY.
    • Oncogene. 2019 Feb;38(8):1166-1182. doi: 10.1038/s41388-018-0506-7. Epub 2018 Sep 25.
    • Treating metastatic breast cancer: Analysis of the impact of palbociclib (Ibrance) on overall survival in the PALOMA-3 trial.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 23.
    • Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    • Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J.
    • Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2.
    • BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
    • Semmler L, Reiter-Brennan C, Klein A.
    • J Breast Cancer. 2019 Jan 22;22(1):1-14. doi: 10.4048/jbc.2019.22.e6. eCollection 2019 Mar.
    • Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    • Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.
    • Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32143. [Epub ahead of print]
    • The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    • Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    • Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
    • Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    • Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH.
    • BMC Cancer. 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4.
    • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    • Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A.
    • Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
    • ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
    • Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP.
    • Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2.
    • Correcting errors in the BRCA1 warning system.
    • Liang Y, Dearnaley WJ, Alden NA, Solares MJ, Gilmore BL, Pridham KJ, Varano AC, Sheng Z, Alli E, Kelly DF.
    • DNA Repair (Amst). 2019 Jan;73:120-128. doi: 10.1016/j.dnarep.2018.11.009. Epub 2018 Nov 22.
    • Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    • Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H.
    • Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
    • Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
    • Mattoo AR, Joun A, Jessup JM.
    • Mol Cancer Res. 2019 Jan;17(1):42-53. doi: 10.1158/1541-7786.MCR-18-0650. Epub 2018 Sep 10.
    • Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
    • Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.
    • Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.
    • Downregulation of TGF-β1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling.
    • Wang Y, Xiang J, Wang J, Ji Y.
    • Biol Res. 2018 Dec 29;51(1):58. doi: 10.1186/s40659-018-0205-4.
    • How latent viruses cause breast cancer: An explanation based on the microcompetition model.
    • Polansky H, Schwab H.
    • Bosn J Basic Med Sci. 2018 Dec 23. doi: 10.17305/bjbms.2018.3950. [Epub ahead of print]
    • Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
    • Campbell AM, Morris M, Gallagher R, Boyd R, Carson H, Harkin DP, Wielogorska E, Elliott C, Savage KI, McIntosh SA.
    • BMJ Open. 2018 Dec 22;8(12):e023115. doi: 10.1136/bmjopen-2018-023115.
    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
    • Kim SE, Baek HJ, Park EJ, Lim SC, Kim SS.
    • Anal Cell Pathol (Amst). 2018 Dec 17;2018:8120579. doi: 10.1155/2018/8120579. eCollection 2018.
    • The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    • Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, Jonkers J, Rottenberg S, Chapman JR.
    • Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.
    • BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression.
    • Zhang X, Li R.
    • Cancers (Basel). 2018 Dec 14;10(12). pii: E513. doi: 10.3390/cancers10120513.
    • Differences in the Neanderthal BRCA2 gene might be related to their distinctive cognitive profile.
    • Benítez-Burraco A.
    • Hereditas. 2018 Dec 13;155:38. doi: 10.1186/s41065-018-0076-2. eCollection 2018.

    Original Research:

    Unique divergence of the breast cancer 2 (BRCA2) gene in Neanderthals.

    • PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    • Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.
    • Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
    • Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M.
    • Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP.
    • Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):173-177. doi: 10.1016/j.bbrc.2018.11.001. Epub 2018 Nov 8.

    Press: Novel Blood Test a Potential 'Game Changer' in Ovarian Cancer. (Medscape Oncology)

    • Variation in RAD51 details a hub of functions: opportunities to advance cancer diagnosis and therapy.
    • van der Zon NL, Kanaar R, Wyman C.
    • Version 2. F1000Res. 2018 Sep 12 [revised 2018 Dec 3];7. pii: F1000 Faculty Rev-1453. doi: 10.12688/f1000research.15650.2. eCollection 2018.
    • Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
    • Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L.
    • Int J Cancer. 2018 Dec 1;143(11):2932-2942. doi: 10.1002/ijc.31659. Epub 2018 Oct 3.
    • Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    • Haynes B, Murai J, Lee JM.
    • Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
    • Review
    • PARP-1 regulates DNA repair factor availability.
    • Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e8816. doi: 10.15252/emmm.201708816.
    • Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    • Wang Z, Zhang J, Zhang Y, Deng Q, Liang H.
    • Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
    • Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
    • Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin LA, Gupta S, Mao G, Shekhar MP.
    • Mol Cancer Ther. 2018 Dec;17(12):2586-2597. doi: 10.1158/1535-7163.MCT-18-0364. Epub 2018 Sep 21.
    • Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
    • Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.
    • Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.
    • Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    • Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.
    • J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4.
    • Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis.
    • Soong TR, Kolin DL, Teschan NJ, Crum CP.
    • Cancers (Basel). 2018 Nov 28;10(12). pii: E468. doi: 10.3390/cancers10120468.
    • Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
    • Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y.
    • ACS Nano. 2018 Nov 27;12(11):10785-10796. doi: 10.1021/acsnano.8b01573. Epub 2018 Nov 12.
    • Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast.
    • Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M.
    • Oncotarget. 2018 Nov 20;9(91):36379-36391. doi: 10.18632/oncotarget.26372. eCollection 2018 Nov 20.
    • Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    • Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.
    • PLoS One. 2018 Nov 16;13(11):e0207399. doi: 10.1371/journal.pone.0207399. eCollection 2018.
    • PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
    • Beck C, Rodriguez-Vargas JM, Boehler C, Robert I, Heyer V, Hanini N, Gauthier LR, Tissier A, Schreiber V, Elofsson M, Reina San Martin B, Dantzer F.
    • Cell Death Differ. 2018 Nov 15. doi: 10.1038/s41418-018-0233-1. [Epub ahead of print]
    • Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
    • Yousif HMA, Mohammed RAA.
    • Curr Probl Cancer. 2018 Nov 6. pii: S0147-0272(18)30275-7. doi: 10.1016/j.currproblcancer.2018.10.003. [Epub ahead of print]
    • Secondary cytoreduction in ovarian cancer: who really benefits?
    • Giudice MT, D'Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, Petrillo M.
    • Arch Gynecol Obstet. 2018 Nov;298(5):873-879. doi: 10.1007/s00404-018-4915-1. Epub 2018 Sep 25.
    • Review
    • Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells.
    • Jin Q, Noel O, Nguyen M, Sam L, Gerhard GS.
    • Eur J Cancer Prev. 2018 Nov;27(6):553-556. doi: 10.1097/CEJ.0000000000000398.
    • Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
    • Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.
    • J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93.
    • Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
    • Mukhopadhyay A, Drew Y, Matheson , Salehan , Gentles , Pachter JA, Curtin NJ.
    • Biochem Pharmacol. 2018 Oct 17. pii: S0006-2952(18)30432-5. doi: 10.1016/j.bcp.2018.10.011. [Epub ahead of print]
    • Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
    • Choi EK, Lim JA, Kim JK, Jang MS, Kim SE, Baek HJ, Park EJ, Kim TH, Deng CX, Wang RH, Kim SS.
    • Exp Mol Med. 2018 Oct 16;50(10):136. doi: 10.1038/s12276-018-0169-z.
    • Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
    • Baek HJ, Kim SE, Kim JK, Shin DH, Kim TH, Kim KG, Deng CX, Kim SS.
    • Int J Biol Sci. 2018 Oct 3;14(13):1769-1781. doi: 10.7150/ijbs.29242. eCollection 2018.
    • Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation.
    • Baek HJ, Kim SE, Choi EK, Kim JK, Shin DH, Park EJ, Kim TH, Kim JY, Kim KG, Deng CX, Kim SS.
    • Int J Biol Sci. 2018 Oct 3;14(12):1755-1768. doi: 10.7150/ijbs.28142. eCollection 2018.
    • Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.
    • De La Cruz LM, Czerniecki BJ.
    • Ann Surg Oncol. 2018 Oct;25(10):2852-2857. doi: 10.1245/s10434-018-6620-5. Epub 2018 Jul 16.
    • Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    • Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.
    • Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.
    • Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
    • Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.
    • J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.
    • Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    • Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.
    • Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
    • BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    • Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N.
    • Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086.
    • Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks.
    • Whelan DR, Lee WTC, Yin Y, Ofri DM, Bermudez-Hernandez K, Keegan S, Fenyo D, Rothenberg E.
    • Nat Commun. 2018 Sep 24;9(1):3882. doi: 10.1038/s41467-018-06435-3.
    • Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
    • Buckley AR, Ideker T, Carter H, Harismendy O, Schork NJ.
    • Genome Med. 2018 Sep 14;10(1):69. doi: 10.1186/s13073-018-0579-5.
    • MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
    • Milevskiy MJG, Sandhu GK, Wronski A, Korbie D, Brewster BL, Shewan A, Edwards SL, French JD, Brown MA.
    • Oncotarget. 2018 Sep 11;9(71):33577-33588. doi: 10.18632/oncotarget.26094. eCollection 2018 Sep 11.

    Comment:

    MiRNAs prognostic for basal and BRCA1 breast cancer.

    • Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    • Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    • Gynecol Oncol. 2018 Sep;150(3):534-544. doi: 10.1016/j.ygyno.2018.07.002. Epub 2018 Jul 17.
    • Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    • Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.
    • Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
    • BRCA2 protects mammalian cells from heat shock.
    • Nakagawa Y, Kajihara A, Takahashi A, Murata AS, Matsubayashi M, Ito SS, Ota I, Nakagawa T, Hasegawa M, Kirita T, Ohnishi T, Mori E.
    • Int J Hyperthermia. 2018 Sep;34(6):795-801. doi: 10.1080/02656736.2017.1370558. Epub 2017 Sep 10.
    • BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
    • van de Ven M, Liu X, van der Burg E, Klarenbeek S, Alexi X, Zwart W, Dijcks F, Bouwman P, Jonkers J.
    • J Pathol. 2018 Sep;246(1):41-53. doi: 10.1002/path.5105. Epub 2018 Jul 4.
    • Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities.
    • Casey AE, Sinha A, Singhania R, Livingstone J, Waterhouse P, Tharmapalan P, Cruickshank J, Shehata M, Drysdale E, Fang H, Kim H, Isserlin R, Bailey S, Medina T, Deblois G, Shiah YJ, Barsyte-Lovejoy D, Hofer S, Bader G, Lupien M, Arrowsmith C, Knapp S, De Carvalho D, Berman H, Boutros PC, Kislinger T, Khokha R.
    • J Cell Biol. 2018 Aug 6;217(8):2951-2974. doi: 10.1083/jcb.201804042. Epub 2018 Jun 19.

    Press: Breast Cancer Epigenetics Study Reveals Potential Drug Targets. (Clinical OMICs)

    • Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants.
    • Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Infante M, Durán M, Marcos G, Lastra E, Gómez-Barrero S, Velasco EA.
    • Breast Cancer Res Treat. 2018 Aug;171(1):53-63. doi: 10.1007/s10549-018-4826-7. Epub 2018 May 15.
    • Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    • Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.
    • Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
    • PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    • Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X.
    • J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.
    • Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1-PALB2 Interaction.
    • Mahdi AH, Huo Y, Tan Y, Simhadri S, Vincelli G, Gao J, Ganesan S, Xia B.
    • Cancer Res. 2018 Jul 15;78(14):3969-3981. doi: 10.1158/0008-5472.CAN-18-0388. Epub 2018 May 8.
    • Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
    • El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.
    • Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    • Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    • Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
    • Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    • Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.
    • Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.
    • Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    • Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F.
    • Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.
    • A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    • Trenner A, Godau J, Sartori AA.
    • Mol Cancer Ther. 2018 Jul;17(7):1392-1404. doi: 10.1158/1535-7163.MCT-17-1156. Epub 2018 Apr 13.
    • BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
    • Hollingsworth J, Lau A, Tone A, Kollara A, Allen L, Colgan TJ, Dube V, Rosen B, Murphy KJ, Greenblatt EM, Feigenberg T, Virtanen C, Brown TJ.
    • Neoplasia. 2018 Jul;20(7):697-709. doi: 10.1016/j.neo.2018.05.005. Epub 2018 May 28.
    • Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.
    • Jin Z, Xu L, Zhang L, Zhao M, Li D, Ye L, Ma Y, Ren S, Yu H, Wang D, Liang C, Chen B.
    • Am J Transl Res. 2018 Jun 15;10(6):1677-1689. eCollection 2018.
    • Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    • Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.
    • Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.
    • Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    • Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie D, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.
    • Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.
    • Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
    • Zhu Q, Hoong N, Aslanian A, Hara T, Benner C, Heinz S, Miga KH, Ke E, Verma S, Soroczynski J, Yates JR 3rd, Hunter T, Verma IM.
    • Mol Cell. 2018 Jun 7;70(5):842-853.e7. doi: 10.1016/j.molcel.2018.04.023. Epub 2018 May 31.
    • Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    • Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.
    • Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.
    • Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15.
    • Madsen MJ, Knight S, Sweeney C, Factor R, Salama M, Stijleman IJ, Rajamanickam V, Welm BE, Arunachalam S, Jones B, Rachamadugu R, Rowe K, Cessna MH, Thomas A, Kushi LH, Caan BJ, Bernard PS, Camp NJ.
    • Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):644-652. doi: 10.1158/1055-9965.EPI-17-0887. Epub 2018 Apr 12.
    • Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    • Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.
    • Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.
    • Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.
    • Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Suzuki A, Ohuchi N, Ishida T.
    • Cancer Sci. 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.
    • The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    • Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.
    • Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
    • Heat-induced BRCA2 degradation in human tumors provides rationale for hyperthermia-PARP-inhibitor combination therapies.
    • van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent D, Hardillo J, Verduijn G, Drooger J, van Rhoon G, Smedts D, van Doorn H, Boormans J, Jager A, Franckena M, Kanaar R.
    • Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.
    • Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition.
    • Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J.
    • Mol Cancer Res. 2018 Jun;16(6):961-973. doi: 10.1158/1541-7786.MCR-17-0607. Epub 2018 Mar 15.
    • APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
    • Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB.
    • Mol Cancer Ther. 2018 Jun;17(6):1167-1176. doi: 10.1158/1535-7163.MCT-17-0834. Epub 2018 Apr 6.
    • Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    • Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, Gozzi G, Alberti L, Fabbiani L, Botticelli L, Benhattar J.
    • Int J Mol Sci. 2018 May 24;19(6). pii: E1559. doi: 10.3390/ijms19061559.
    • Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.
    • Pavanello S, Varesco L, Gismondi V, Bruzzi P, Bolognesi C.
    • PLoS One. 2018 May 21;13(5):e0197522. doi: 10.1371/journal.pone.0197522. eCollection 2018.
    • Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
    • Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA.
    • Dis Model Mech. 2018 May 18;11(5). pii: dmm032292. doi: 10.1242/dmm.032292.
    • Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
    • Wezyk M, Zekanowski C.
    • ACS Chem Neurosci. 2018 May 16;9(5):870-872. doi: 10.1021/acschemneuro.8b00149. Epub 2018 Apr 10.
    • Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
    • Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.
    • Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.
    • DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
    • Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, Typas D, Lammers M, Mailand N, Nussenzweig A, Lukas J, Choudhary C.
    • Cell. 2018 May 3;173(4):972-988.e23. doi: 10.1016/j.cell.2018.03.050. Epub 2018 Apr 12.
    • BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development.
    • Kitami K, Kitami M, Kaku M, Wang B, Komatsu Y.
    • PLoS Genet. 2018 May 2;14(5):e1007340. doi: 10.1371/journal.pgen.1007340. [Epub ahead of print]
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • Brca1 Is Upregulated by 5-Aza-CdR and Promotes DNA Repair and Cell Survival, and Inhibits Neurite Outgrowth in Rat Retinal Neurons.
    • Wang Q, Xu L, Chen P, Xu Z, Qiu J, Ge J, Yu K, Zhuang J.
    • Int J Mol Sci. 2018 Apr 17;19(4). pii: E1214. doi: 10.3390/ijms19041214.
    • PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    • Turk AA, Wisinski KB.
    • Cancer. 2018 Apr 16. doi: 10.1002/cncr.31307. [Epub ahead of print]
    • Review
    • Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    • Ren D, Zhu X, Kong R, Zhao Z, Sheng J, Wang J, Xu X, Liu J, Cui K, Zhang XH, Zhao H, Wong STC.
    • Cancer Res. 2018 Apr 15;78(8):2052-2064. doi: 10.1158/0008-5472.CAN-17-2994. Epub 2018 Mar 22.
    • Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
    • Dasa SSK, Diakova G, Suzuki R, Mills AM, Gutknecht MF, Klibanov AL, Slack-Davis JK, Kelly KA.
    • Theranostics. 2018 Apr 11;8(10):2782-2798. doi: 10.7150/thno.23050. eCollection 2018.
    • Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    • Hu Z, Shen R, Campbell A, McMichael EL, Yu L, Ramaswamy B, London CA, Xu T, Carson WE.
    • Cancer Immunol Res. 2018 Apr 5. pii: canimm.0343.2017. doi: 10.1158/2326-6066.CIR-17-0343. [Epub ahead of print]
    • Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    • Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.
    • Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    • Park KJ, Patel P, Linkov I, Jotwani A, Kauff N, Pike MC.
    • Histopathology. 2018 Apr;72(5):766-776. doi: 10.1111/his.13444. Epub 2018 Jan 29.
    • PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    • Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.
    • Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.
    • Proteomics Analysis to Assess the Role of Mitochondria in BRCA1-Mediated Breast Tumorigenesis.
    • Concolino A, Olivo E, Tammè L, Fiumara CV, De Angelis MT, Quaresima B, Agosti V, Costanzo FS, Cuda G, Scumaci D.
    • Proteomes. 2018 Mar 27;6(2). pii: E16. doi: 10.3390/proteomes6020016.
    • Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    • Tang YC, Ho SC, Tan E, Ng AWT, McPherson JR, Goh GYL, Teh BT, Bard F, Rozen SG.
    • Breast Cancer Res. 2018 Mar 22;20(1):22. doi: 10.1186/s13058-018-0949-3.
    • Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
    • Carvajal R, Fernández J, García N, López A, Gutiérrez-Enríquez S, Diez O, Benítez J, Salinas M, Teulé A, Brunet J, Radice P, Peterlongo P, Schindler D, Huertas P, Puente XS, Lázaro C, Pujana MÀ, Surrallés J.
    • Nat Commun. 2018 Mar 6;9(1):967. doi: 10.1038/s41467-018-03433-3.
    • Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.
    • Semushina SG, Aronov DA, Moiseeva EV.
    • Pathol Oncol Res. 2018 Mar 6. doi: 10.1007/s12253-018-0396-6. [Epub ahead of print]
    • Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    • Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.
    • Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.
    • Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
    • Chen CC, Feng W, Lim PX, Kass EM, Jasin M.
    • Annu Rev Cancer Biol. 2018 Mar;2:313-336. doi: 10.1146/annurev-cancerbio-030617-050502. Epub 2017 Dec 1.
    • Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    • Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    • Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
    • Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.
    • Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.
    • Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4.
    • BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.
    • Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F.
    • Int J Gynecol Cancer. 2018 Mar;28(3):472-478. doi: 10.1097/IGC.0000000000001214.
    • Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    • Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.
    • Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.
    • BRCA1 through its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
    • Vázquez-Arreguín K, Maddox J, Kang J, Park D, Cano RR, Factor RE, Ludwig T, Tantin D.
    • Mol Cancer Res. 2018 Mar;16(3):439-452. doi: 10.1158/1541-7786.MCR-17-0364. Epub 2018 Jan 12.
    • RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
    • Rao S, Cronin SJF, Sigl V, Penninger JM.
    • Trends Cell Biol. 2018 Mar;28(3):213-223. doi: 10.1016/j.tcb.2017.11.001. Epub 2017 Dec 11.
    • Review
    • Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?
    • Yan S, Wu G.
    • Oncotarget. 2017 Dec 22;9(15):12503-12512. doi: 10.18632/oncotarget.23605. eCollection 2018 Feb 23.
    • MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
    • Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.
    • Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.
    • Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    • Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, Chen Y, Ding J, Xu Y, Miao Z, Yang C.
    • Eur J Med Chem. 2018 Feb 10;145:389-403. doi: 10.1016/j.ejmech.2018.01.018. Epub 2018 Jan 8.
    • BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes.
    • Stewart MD, Zelin E, Dhall A, Walsh T, Upadhyay E, Corn JE, Chatterjee C, King MC, Klevit RE.
    • Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1316-1321. doi: 10.1073/pnas.1715467115. Epub 2018 Jan 24.
    • Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
    • Kim JL, Ha GH, Campo L, Breuer EK.
    • Biochem Biophys Res Commun. 2018 Feb 5;496(2):633-640. doi: 10.1016/j.bbrc.2018.01.101. Epub 2018 Jan 19.
    • Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.
    • Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I.
    • Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.
    • Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.
    • Tayyari F, Gowda GAN, Olopade OF, Berg R, Yang HH, Lee MP, Ngwa WF, Mittal SK, Raftery D, Mohammed SI.
    • Oncotarget. 2018 Feb 7;9(14):11677-11690. doi: 10.18632/oncotarget.24433. eCollection 2018 Feb 20.
    • Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer.
    • Natanzon Y, Earp M, Cunningham JM, Kalli KR, Wang C, Armasu SM, Larson MC, Bowtell DD, Garsed DW, Fridley BL, Winham SJ, Goode EL.
    • Cancer Inform. 2018 Feb 1;17:1176935118755341. doi: 10.1177/1176935118755341. eCollection 2018.
    • Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    • Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.
    • Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.
    • NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer.
    • Sau A, Cabrita MA, Pratt MAC.
    • Cancer Prev Res (Phila). 2018 Feb;11(2):69-80. doi: 10.1158/1940-6207.CAPR-17-0225. Epub 2017 Nov 3.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study.
    • Dey S, Marino N, Bishop K, Dahlgren PN, Shendre A, Storniolo AM, He C, Tanaka H.
    • Oncotarget. 2017 Dec 29;9(3):4214-4222. doi: 10.18632/oncotarget.23767. eCollection 2018 Jan 9.
    • Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
    • Sengodan SK, Rajan A, Hemalatha SK, Nadhan R, Jaleel A, Srinivas P.
    • J Proteome Res. 2018 Jan 5;17(1):276-289. doi: 10.1021/acs.jproteome.7b00562. Epub 2017 Nov 7.
    • Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    • Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.
    • Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
    • MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    • Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.
    • Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.
    • Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
    • Privat M, Rudewicz J, Sonnier N, Tamisier C, Ponelle-Chachuat F, Bignon YJ.
    • Int J Med Sci. 2018 Jan 1;15(1):46-58. doi: 10.7150/ijms.20508. eCollection 2018.
    • Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer.
    • Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, Xie X, Xiao X.
    • Biomed Pharmacother. 2018 Jan;97:1275-1281. doi: 10.1016/j.biopha.2017.11.055. Epub 2017 Dec 14.
    • Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
    • Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Cancer Sci. 2018 Jan;109(1):166-173. doi: 10.1111/cas.13426. Epub 2017 Nov 10.
    • A Novel Model to Characterize Structure and Function of BRCA1.
    • Lin D, Izadpanah R, Braun SE, Alt E.
    • Cell Biol Int. 2018 Jan;42(1):34-44. doi: 10.1002/cbin.10846. Epub 2017 Oct 25.
    • Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    • Wan B, Dai L, Wang L, Zhang Y, Huang H, Qian G, Yu T.
    • Endocr Relat Cancer. 2018 Jan;25(1):69-82. doi: 10.1530/ERC-17-0261. Epub 2017 Oct 24.
    • Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
    • Yeo SK, Paul R, Haas M, Wang C, Guan JL.
    • Autophagy. 2018;14(7):1214-1225. doi: 10.1080/15548627.2018.1460010. Epub 2018 Jul 20.
    • DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    • Misenko SM, Patel DS, Her J, Bunting SF.
    • Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.
    • Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease.
    • Wezyk M, Szybinska A, Wojsiat J, Szczerba M, Day K, Ronnholm H, Kele M, Berdynski M, Peplonska B, Fichna JP, Ilkowski J, Styczynska M, Barczak A, Zboch M, Filipek-Gliszczynska A, Bojakowski K, Skrzypczak M, Ginalski K, Kabza M, Makalowska I, Barcikowska-Kotowicz M, Wojda U, Falk A, Zekanowski C.
    • J Alzheimers Dis. 2018;62(1):175-202. doi: 10.3233/JAD-170830.
    • Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.
    • Benítez-Buelga C, Baquero JM, Vaclova T, Fernández V, Martín P, Inglada-Perez L, Urioste M, Osorio A, Benítez J.
    • Oncotarget. 2017 Nov 23;8(70):114626-114636. doi: 10.18632/oncotarget.22638. eCollection 2017 Dec 29.
    • Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
    • Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.
    • Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.
    • HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
    • Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN.
    • Oncotarget. 2017 Dec 12;8(69):114156-114172. doi: 10.18632/oncotarget.23169. eCollection 2017 Dec 26.
    • [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    • Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Dec 25;52(12):835-843. doi: 10.3760/cma.j.issn.0529-567x.2017.12.008.
    • [Article in Chinese]
    • BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    • Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.
    • Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
    • Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.
    • Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM.
    • Oncotarget. 2017 Oct 31;8(67):111026-111040. doi: 10.18632/oncotarget.22195. eCollection 2017 Dec 19.
    • Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
    • Roig B, Rodríguez-Balada M, Samino S, Lam EW, Guaita-Esteruelas S, Gomes AR, Correig X, Borràs J, Yanes O, Gumà J.
    • Sci Rep. 2017 Dec 19;7(1):17831. doi: 10.1038/s41598-017-17897-8.
    • Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    • Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.
    • PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017.
    • High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer.
    • Li J, Li M, Chen P, Ba Q.
    • FEBS Open Bio. 2017 Dec 13;8(1):56-63. doi: 10.1002/2211-5463.12356. eCollection 2018 Jan.
    • MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    • Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY.
    • Cancer Res. 2017 Dec 1;77(23):6641-6650. doi: 10.1158/0008-5472.CAN-16-3452. Epub 2017 Sep 26.
    • Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2-ovarian cancers.
    • Bueno R, Mar JC.
    • Methods. 2017 Dec 1;131:74-82. doi: 10.1016/j.ymeth.2017.07.021. Epub 2017 Jul 25.
    • Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.
    • Su C, Gius JP, Van Steenberg J, Haskins AH, Heishima K, Omata C, Iwayama M, Murakami M, Mori T, Maruo K, Kato TA.
    • Sci Rep. 2017 Dec 1;7(1):16704. doi: 10.1038/s41598-017-16795-3.
    • BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
    • Nathan S, Ma Y, Tomita YA, De Oliveira E, Brown ML, Rosen EM.
    • Breast Cancer Res Treat. 2017 Dec;166(3):681-693. doi: 10.1007/s10549-017-4442-y. Epub 2017 Aug 14.
    • Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
    • Zhang X, Hofmann S, Harbeck N, Jeschke U, Sixou S.
    • Drugs R D. 2017 Dec;17(4):569-583. doi: 10.1007/s40268-017-0208-6.
    • Mechanism of tandem duplication formation in BRCA1-mutant cells.
    • Willis NA, Frock RL, Menghi F, Duffey EE, Panday A, Camacho V, Hasty EP, Liu ET, Alt FW, Scully R.
    • Nature. 2017 Nov 30;551(7682):590-595. doi: 10.1038/nature24477. Epub 2017 Nov 22.
    • Nanopore sequencing of full-length BRCA1 mRNA transcripts reveals co-occurrence of known exon skipping events.
    • de Jong LC, Cree S, Lattimore V, Wiggins GAR, Spurdle AB; kConFab Investigators, Miller A, Kennedy MA, Walker LC.
    • Breast Cancer Res. 2017 Nov 28;19(1):127. doi: 10.1186/s13058-017-0919-1.
    • Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
    • Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S, Chen J, Tomsky K, Xie H, Khella CA, Gatza ML, Xia D, Gao J, White E, Haffty BG, Hu W, Feng Z.
    • Nat Commun. 2017 Nov 28;8(1):1823. doi: 10.1038/s41467-017-01947-w.
    • A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
    • Ryan D, Bogan D, Davies J, Koziol J, ElShamy WM.
    • Oncotarget. 2017 Sep 14;8(61):103182-103206. doi: 10.18632/oncotarget.20892. eCollection 2017 Nov 28.
    • Never tear us a-PARP: Dealing with DNA lesions during mitosis.
    • Schoonen PM, van Vugt MATM.
    • Mol Cell Oncol. 2017 Oct 31;5(1):e1382670. doi: 10.1080/23723556.2017.1382670. eCollection 2018.
    • PARP inhibition causes premature loss of cohesion in cancer cells.
    • Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.
    • Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28.
    • Antitumor Activity of Copper (I)-Nicotinate Complex and Autophagy Modulation in HCC1806 Breast Cancer Cells.
    • Abdel-Mohsen MA, El-Shafey ES, Malak CA, Abou-Yossef MM.
    • Anticancer Agents Med Chem. 2017 Nov 24;17(11):1526-1536. doi: 10.2174/1871520617666170327144122.
    • Graph-theoretical comparison of normal and tumor networks in identifying BRCA genes.
    • Dopazo J, Erten C.
    • BMC Syst Biol. 2017 Nov 22;11(1):110. doi: 10.1186/s12918-017-0495-0.
    • The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis.
    • Fujimoto M, Takii R, Takaki E, Katiyar A, Nakato R, Shirahige K, Nakai A.
    • Nat Commun. 2017 Nov 21;8(1):1638. doi: 10.1038/s41467-017-01807-7.
    • The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    • Hromas R, Kim HS, Sidhu G, Williamson E, Jaiswal A, Totterdale TA, Nole J, Lee SH, Nickoloff JA, Kong KY./li>
    • Breast Cancer Res. 2017 Nov 16;19(1):122. doi: 10.1186/s13058-017-0912-8.
    • Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.
    • Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P, Rottenberg S.
    • Clin Cancer Res. 2017 Nov 15;23(22):7020-7033. doi: 10.1158/1078-0432.CCR-17-1279. Epub 2017 Aug 18.
    • The Long Noncoding RNA HOTAIR in Breast Cancer: Does Autophagy Play a Role?
    • Pawłowska E, Szczepanska J, Blasiak J.
    • Int J Mol Sci. 2017 Nov 3;18(11). pii: E2317. doi: 10.3390/ijms18112317.
    • The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
    • Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.
    • Oncol Res. 2017 Nov 2;25(9):1441-1451. doi: 10.3727/096504017X14926854178616. Epub 2017 Apr 20.
    • Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    • Barrdahl M, Rudolph A, Hopper JL, Southey MC, Broeks A, Fasching PA, Beckmann MW, Gago-Dominguez M, Castelao JE, Guénel P, Truong T, Bojesen SE, Gapstur SM, Gaudet MM, Brenner H, Arndt V, Brauch H, Hamann U, Mannermaa A, Lambrechts D, Jongen L, Flesch-Janys D, Thoene K, Couch FJ, Giles GG, Simard J, Goldberg MS, Figueroa J, Michailidou K, Bolla MK, Dennis J, Wang Q, Eilber U, Behrens S, Czene K, Hall P, Cox A, Cross S, Swerdlow A, Schoemaker MJ, Dunning AM, Kaaks R, Pharoah PDP, Schmidt M, Garcia-Closas M, Easton DF, Milne RL, Chang-Claude J.
    • Int J Cancer. 2017 Nov 1;141(9):1830-1840. doi: 10.1002/ijc.30859. Epub 2017 Aug 11.
    • Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    • Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.
    • J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx062.
    • Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    • Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang H, Ding J, Ren GB, Miao ZH, Li J.
    • Acta Pharmacol Sin. 2017 Nov;38(11):1521-1532. doi: 10.1038/aps.2017.104. Epub 2017 Aug 3.
    • Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
    • Mazumder S, Johnson JM, Swank V, Dvorina N, Martelli E, Ko J, Tuohy VK.
    • Cancer Prev Res (Phila). 2017 Nov;10(11):612-624. doi: 10.1158/1940-6207.CAPR-17-0154.

    Editorial:

    Targeting "Retired Antigens" for Cancer Immunoprevention.

    • Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
    • Trafalis DT, Polonifi A, Dalezis P, Nikoleousakos N, Katsamakas S, Sarli V.
    • Chem Biol Drug Des. 2017 Nov;90(5):854-866. doi: 10.1111/cbdd.13006. Epub 2017 May 26.
    • Deciphering the role of microRNA - A step by step guide.
    • Manvati S, Mangalhara KC, Khan J, Pathania GL, Kaul S, Kaushik M, Arora A, Dhar PK.
    • Gene Expr Patterns. 2017 Nov;25-26:59-65. doi: 10.1016/j.gep.2017.06.002. Epub 2017 Jun 8.
    • Review
    • TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
    • Abo MA, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.
    • Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.
    • EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
    • Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.
    • Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.
    • Doubling Down on BRCA-Mutated Cancer.
    • Wahner Hendrickson AE, Kaufmann SH, Swisher EM.
    • Trends Cancer. 2017 Nov;3(11):743-744. doi: 10.1016/j.trecan.2017.09.005. Epub 2017 Sep 29.
    • Review
    • Never tear us a-PARP: Dealing with DNA lesions during mitosis.
    • Schoonen PM, van Vugt MATM.
    • Mol Cell Oncol. 2017 Oct 31;5(1):e1382670. doi: 10.1080/23723556.2017.1382670. eCollection 2018.
    • The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells.
    • Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN.
    • J Cancer. 2017 Oct 23;8(19):4048-4056. doi: 10.7150/jca.21338. eCollection 2017.
    • FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2.
    • Porro A, Berti M, Pizzolato J, Bologna S, Kaden S, Saxer A, Ma Y, Nagasawa K, Sartori AA, Jiricny J.
    • Nat Commun. 2017 Oct 20;8(1):1073. doi: 10.1038/s41467-017-01074-6.
    • Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers.
    • Taglialatela A, Alvarez S, Leuzzi G, Sannino V, Ranjha L, Huang JW, Madubata C, Anand R, Levy B, Rabadan R, Cejka P, Costanzo V, Ciccia A.
    • Mol Cell. 2017 Oct 19;68(2):414-430.e8. doi: 10.1016/j.molcel.2017.09.036.
    • Roles of BCCIP deficiency in mammary tumorigenesis.
    • Droz-Rosario R, Lu H, Liu J, Liu NA, Ganesan S, Xia B, Haffty BG, Shen Z.
    • Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.
    • The role of Rak in the regulation of stability and function of BRCA1.
    • Kim JL, Ha GH, Campo L, Denning MF, Patel TB, Osipo C, Lin SY, Breuer EK.
    • Oncotarget. 2015 Oct 14;8(49):86799-86815. doi: 10.18632/oncotarget.5717. eCollection 2017 Oct 17.
    • Replication fork reversal triggers fork degradation in BRCA2-defective cells.
    • Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, Ursich S, Ray Chaudhuri A, Nussenzweig A, Janscak P, Lopes M.
    • Nat Commun. 2017 Oct 16;8(1):859. doi: 10.1038/s41467-017-01164-5.
    • MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
    • Lemaçon D, Jackson J, Quinet A, Brickner JR, Li S, Yazinski S, You Z, Ira G, Zou L, Mosammaparast N, Vindigni A.
    • Nat Commun. 2017 Oct 16;8(1):860. doi: 10.1038/s41467-017-01180-5.
    • BRCA1-BARD1 Activates RAD51 for DNA Repair by Homologous Recombination.
    • [No authors listed]
    • Cancer Discov. 2017 Oct 13. doi: 10.1158/2159-8290.CD-RW2017-195. [Epub ahead of print]
    • Research news
    • PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells.
    • Su C, Haskins AH, Omata C, Aizawa Y, Kato TA.
    • Pharmaceuticals (Basel). 2017 Oct 12;10(4). pii: E80. doi: 10.3390/ph10040080.
    • Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.
    • Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, Norton L, Weigelt B, Powell SN, Reis-Filho JS.
    • Nat Commun. 2017 Oct 11;8(1):857. doi: 10.1038/s41467-017-00921-w.
    • Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
    • Sharma M, Piplani S, Madan M, Manjari M, Garg S, Kaur K.
    • Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):469-474. doi: 10.4103/IJPM.IJPM_524_16.
    • PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
    • Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P.
    • Biomed Pharmacother. 2017 Oct;94:944-954. doi: 10.1016/j.biopha.2017.07.151. Epub 2017 Aug 12.
    • Thwarting endogenous stress: BRCA protects against aldehyde toxicity.
    • Ray Chaudhuri A, Nussenzweig A.
    • EMBO Mol Med. 2017 Oct;9(10):1331-1333. doi: 10.15252/emmm.201708194.
    • BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
    • Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matía García V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2017 Oct;9(10):1398-1414. doi: 10.15252/emmm.201607446.

    Research report, Commentary:

    Thwarting endogenous stress: BRCA protects against aldehyde toxicity.

    • P53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.
    • Wang X, El-Halaby AA, Zhang H, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG.
    • Hum Pathol. 2017 Oct;68:22-25. doi: 10.1016/j.humpath.2017.04.007. Epub 2017 Apr 21.
    • Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
    • Griscelli F, Oudrhiri N, Feraud O, Divers D, Portier L, Turhan AG, Bennaceur Griscelli A.
    • Stem Cell Res. 2017 Oct;24:135-138. doi: 10.1016/j.scr.2017.09.003. Epub 2017 Sep 14.
    • BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    • Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.
    • Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.
    • Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    • Chen W, Guo N, Qi M, Dai H, Hong M, Guan L, Huan X, Song S, He J, Wang Y, Xi Y, Yang X, Shen Y, Su Y, Sun Y, Gao Y, Chen Y, Ding J, Tang Y, Ren G, Miao Z, Li J.
    • Eur J Med Chem. 2017 Sep 29;138:514-531. doi: 10.1016/j.ejmech.2017.06.053. Epub 2017 Jun 27.
    • Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.
    • Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S.
    • Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017.
    • Beyond interstrand crosslinks repair: Contribution of FANCD2 and other Fanconi Anemia proteins to the replication of DNA.
    • Federico MB, Campodónico P, Paviolo NS, Gottifredi V.
    • Mutat Res. 2017 Sep 25. pii: S0027-5107(17)30167-7. doi: 10.1016/j.mrfmmm.2017.09.006. [Epub ahead of print]
    • Review
    • Structural analysis of BRCA1 reveals modification hotspot.
    • Liang Y, Dearnaley WJ, Varano AC, Winton CE, Gilmore BL, Alden NA, Sheng Z, Kelly DF.
    • Sci Adv. 2017 Sep 20;3(9):e1701386. doi: 10.1126/sciadv.1701386. eCollection 2017 Sep.
    • Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
    • Qin T, Huang G, Chi L, Sui S, Song C, Li N, Sun S, Li N, Zhang M, Zhao Z, Li L, Li M.
    • Biomed Pharmacother. 2017 Sep 4;95:649-655. doi: 10.1016/j.biopha.2017.08.095. [Epub ahead of print]
    • BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
    • Sengodan SK, Nadhan R, Nair RS, Hemalatha SK, Somasundaram V, Sushama RR, Rajan A, Latha NR, Varghese GR, Thankappan RK, Kumar JM, Chil A, Anilkumar TV, Srinivas P.
    • Oncogenesis. 2017 Sep 4;6(9):e376. doi: 10.1038/oncsis.2017.75.
    • BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    • Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH, Rauscher GH.
    • PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.
    • Systems analysis of dynamic transcription factor activity identifies targets for treatment in olaparib resistant cancer cells.
    • Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD.
    • Biotechnol Bioeng. 2017 Sep;114(9):2085-2095. doi: 10.1002/bit.26293. Epub 2017 May 18.
    • Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination.
    • Orta ML, Pastor N, Burgos-Morón E, Domínguez I, Calderón-Montaño JM, Huertas Castaño C, López-Lázaro M, Helleday T, Mateos S.
    • DNA Repair (Amst). 2017 Sep;57:116-124. doi: 10.1016/j.dnarep.2017.07.002. Epub 2017 Jul 12.
    • Dynamic real-time in vivo confocal laser endomicroscopy of the fallopian tube during laparoscopy in the prevention of ovarian cancer.
    • Chene G, Chauvy L, Buenerd A, Moret S, Nadaud B, Chabert P, Lamblin G.
    • Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:18-23. doi: 10.1016/j.ejogrb.2017.07.002. Epub 2017 Jul 5.
    • Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
    • Babiker HM, McBride A, Cooke LS, Mahadevan D.
    • Expert Opin Investig Drugs. 2017 Sep;26(9):1063-1072. doi: 10.1080/13543784.2017.1360275. Epub 2017 Jul 30.
    • Review
    • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
    • Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.
    • Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.
    • The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
    • Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA.
    • Int J Mol Sci. 2017 Aug 31;18(9). pii: E1886. doi: 10.3390/ijms18091886.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    • Senhaji Mouhri Z, Goodfellow E, Jean-Claude B.
    • BMC Cancer. 2017 Aug 11;17(1):540. doi: 10.1186/s12885-017-3504-1.
    • Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
    • Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.
    • Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.
    • Identification of new tumor suppressor genes in triple-negative breast cancer.
    • Rangel R, Guzman-Rojas L, Kodama T, Kodama M, Newberg JY, Copeland NG, Jenkins NA.
    • Cancer Res. 2017 Aug 1;77(15):4089-4101. doi: 10.1158/0008-5472.CAN-17-0785. Epub 2017 Jul 19.
    • Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
    • Do TV, Hirst J, Hyter S, Roby KF, Godwin AK.
    • Oncotarget. 2017 Jul 5;8(31):50376-50392. doi: 10.18632/oncotarget.18970. eCollection 2017 Aug 1.
    • TGFbeta and miRNA regulation in familial and sporadic breast cancer.
    • Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.
    • Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.
    • Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
    • Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ.
    • Genes Chromosomes Cancer. 2017 Aug;56(8):589-597. doi: 10.1002/gcc.22459. Epub 2017 May 4.
    • A novel Ubc9 -dependent pathway regulates SIRT1- ER-α Axis and BRCA1-associated TNBC lung metastasis.
    • Xu J, Shumate C, Qin Y, Reddy V, Burnam Y, Lopez V, Okoli J, P Reddy ES, Rao VN.
    • Integr Mol Med. 2017 Aug;4(4). doi: 10.15761/IMM.1000298. Epub 2017 Jul 28.
    • Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
    • Moazzeni H, Najafi A, Khani M.
    • Mol Cell Probes. 2017 Aug;34:45-52. doi: 10.1016/j.mcp.2017.05.005. Epub 2017 May 22.s
    • Effect of Oral Docosahexaenoic Acid (DHA) Supplementation on DHA Levels and Omega-3 Index in Red Blood Cell Membranes of Breast Cancer Patients.
    • Molfino A, Amabile MI, Mazzucco S, Biolo G, Farcomeni A, Ramaccini C, Antonaroli S, Monti M, Muscaritoli M.
    • Front Physiol. 2017 Jul 28;8:549. doi: 10.3389/fphys.2017.00549. eCollection 2017.
    • Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.
    • Jiang D, Turner B, Song J, Li R, Diehn M, Le QT, Khatri P, Koong AC.
    • JCO Precis Oncol. doi: 10.1200/PO.16.00073. Epub 2017 Jul 26.
    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.
    • Chen CC, Kass EM, Yen WF, Ludwig T, Moynahan ME, Chaudhuri J, Jasin M.
    • Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7665-7670. doi: 10.1073/pnas.1706392114. Epub 2017 Jun 28.
    • Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
    • Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.
    • Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.
    • Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    • Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal MA, Bruzzone S, Nencioni A.
    • Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
    • PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    • Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC.
    • Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.
    • Epistasis in genomic and survival data of cancer patients.
    • Matlak D, Szczurek E.
    • PLoS Comput Biol. 2017 Jul 5;13(7):e1005626. doi: 10.1371/journal.pcbi.1005626. [Epub ahead of print]
    • The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    • van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.
    • Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.
    • Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
    • Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa A, Goldenberg DM.
    • Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.
    • Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A, He JX, Miao ZH.
    • Acta Pharmacol Sin. 2017 Jul;38(7):1038-1047. doi: 10.1038/aps.2017.8. Epub 2017 Apr 17.
    • Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
    • Iyer PM, Karthikeyan S, Sanjay Kumar P, Krishnan Namboori PK.
    • Funct Integr Genomics. 2017 Jul;17(4):375-385. doi: 10.1007/s10142-017-0559-7. Epub 2017 May 3.
    • Review
    • Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
    • van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S.
    • Mol Cancer Ther. 2017 Jul;16(7):1279-1289. doi: 10.1158/1535-7163.MCT-16-0740. Epub 2017 May 12.
    • Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
    • Cohen-Sinai T, Cohen Z, Werner H, Berger R.
    • Front Endocrinol (Lausanne). 2017 Jun 29;8:148. doi: 10.3389/fendo.2017.00148. eCollection 2017.
    • Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
    • Denkert C, Liedtke C, Tutt A, von Minckwitz G.
    • Lancet. 2017 Jun 17;389(10087):2430-2442. doi: 10.1016/S0140-6736(16)32454-0. Epub 2016 Dec 7.
    • Review
    • Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.
    • Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L.
    • Cancer Res. 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478. Epub 2017 Apr 20.
    • Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    • Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.
    • Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
    • Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    • Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F.
    • Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.
    • Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
    • de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.
    • Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
    • Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
    • Peplonska B, Bukowska A, Wieczorek E, Przybek M, Zienolddiny S, Reszka E.
    • PLoS One. 2017 Jun 8;12(6):e0178792. doi: 10.1371/journal.pone.0178792. eCollection 2017.
    • Clinical value of R-spondins in triple-negative and metaplastic breast cancers.
    • Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.
    • Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.
    • DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
    • De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner C, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA.
    • Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.
    • Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, Constantinou S, Renaudin X, Lee M, Aebersold R, Venkitaraman AR.
    • Cell. 2017 Jun 1;169(6):1105-1118.e15. doi: 10.1016/j.cell.2017.05.010.

    Preview, Research news:

    Aldehydes Pose a Threat to BRCA2 Mutation Carriers.

    Research news:

    Aldehydes Promote BRCA2 Haploinsufficiency and Genomic Instability.

    Research report, Commentary:

    Thwarting endogenous stress: BRCA protects against aldehyde toxicity.

    • Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    • Yanagawa T, Kagara N, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2017 Jun;163(2):231-240. doi: 10.1007/s10549-017-4190-z. Epub 2017 Mar 10.
    • Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    • Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F.
    • Invest New Drugs. 2017 Jun;35(3):251-259. doi: 10.1007/s10637-016-0424-x. Epub 2017 Jan 23.
    • Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
    • Kawaguchi T, Foster BA, Young J, Takabe K.
    • J Mammary Gland Biol Neoplasia. 2017 Jun;22(2):131-139. doi: 10.1007/s10911-017-9378-7. Epub 2017 Apr 27.
    • Review
    • Non-BRCA familial breast cancer: review of reported pathology and molecular findings.
    • Keeney MG, Couch FJ, Visscher DW, Lindor NM.
    • Pathology. 2017 Jun;49(4):363-370. doi: 10.1016/j.pathol.2017.03.002. Epub 2017 Apr 24.
    • Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
    • Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.
    • Sci Transl Med. 2017 May 31;9(392). pii: eaal5148. doi: 10.1126/scitranslmed.aal5148.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    • Cuyàs E, Corominas-Faja B, Muñoz-San Martín M, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.
    • Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.
    • Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    • Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.
    • Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
    • He Z, Kannan N, Nemirovsky O, Chen H, Connell M, Taylor B, Jiang J, Pilarski LM, Fleisch MC, Niederacher D, Pujana MA, Eaves CJ, Maxwell CA.
    • Oncotarget. 2017 May 16;8(20):32461-32475. doi: 10.18632/oncotarget.15688.
    • Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.
    • Salvati E, Botta L, Amato J, Di Leva FS, Zizza P, Gioiello A, Pagano B, Graziani G, Tarsounas M, Randazzo A, Novellino E, Biroccio A, Cosconati S.
    • J Med Chem. 2017 May 11;60(9):3626-3635. doi: 10.1021/acs.jmedchem.6b01563. Epub 2017 May 1.
    • Transvaginal laparoscopy: A minimally invasive approach to obtain brush cytology of the Fallopian tube.
    • Gordts S, Campo R, Bogers JP, Tanos V, Segaert I, Valkenburg M, Puttemans P, Gordts S.
    • Eur J Obstet Gynecol Reprod Biol. 2017 May;212:80-84. doi: 10.1016/j.ejogrb.2017.03.002. Epub 2017 Mar 12.
    • Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    • El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C.
    • Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6.
    • Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
    • Nair RS, Manoj EP, Thankappan R, Chandrika SK, Kurup MR, Srinivas P.
    • Mol Carcinog. 2017 May;56(5):1501-1514. doi: 10.1002/mc.22610. Epub 2017 Jan 18.
    • Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    • Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.
    • Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525.
    • Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    • Shen J, Liao Y, Hopper JL, Goldberg M, Santella RM, Terry MB.
    • Br J Cancer. 2017 Apr 25;116(9):1229-1233. doi: 10.1038/bjc.2017.81. Epub 2017 Mar 28.
    • Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    • Oei AL, van Leeuwen CM, Ahire VR, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J, Kok HP, Krawczyk PM, Kanaar R, Franken NAP.
    • Oncotarget. 2017 Apr 25;8(17):28116-28124. doi: 10.18632/oncotarget.15922.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • Study Reveals Treatment Strategy for Triple-Negative Breast Cancer.
    • Mateusz Opyrchal
    • OncoTherapy Network. Breast Cancer Targets, AACR 2017. 2017 Apr 20.
    • Video
    • Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    • McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.
    • Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4.
    • Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
    • Smith LD, Leme de Calais F, Raponi M, Mellone M, Buratti E, Blaydes JP, Baralle D.
    • Int J Cancer. 2017 Apr 1;140(7):1564-1570. doi: 10.1002/ijc.30574. Epub 2017 Jan 30.
    • Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.
    • Alothman SJ, Wang W, Goerlitz DS, Islam M, Zhong X, Kishore A, Azhar RI, Kallakury BV, Furth PA.
    • Cancer Prev Res (Phila). 2017 Apr;10(4):244-254. doi: 10.1158/1940-6207.CAPR-16-0268. Epub 2017 Mar 10.
    • Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
    • Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.
    • Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.
    • BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
    • Jamard E, Volard B, Dugué AE, Legros A, Leconte A, Clarisse B, Davy G, Polycarpe F, Dugast C, Abadie C, Frebourg T, Tinat J, Tennevet I, Layet V, Joly F, Castéra L, Berthet P, Vaur D, Krieger S.
    • Fam Cancer. 2017 Apr;16(2):167-171. doi: 10.1007/s10689-016-9940-2.
    • A monograph proposing the use of canine mammary tumours as a model for the study of hereditary breast cancer susceptibility genes in humans.
    • Goebel K, Merner ND.
    • Vet Med Sci. 2017 Mar 21;3(2):51-62. doi: 10.1002/vms3.61. eCollection 2017 May.
    • Transactivation of the estrogen receptor promoter by BRCA1.
    • Archey WB, Arrick BA.
    • Cancer Cell Int. 2017 Mar 2;17:33. doi: 10.1186/s12935-017-0401-2. eCollection 2017.
    • [Fullerene Doxorubicin Nanotransporter for Target Interaction with mutated gene BRCA2].
    • Skaličková S, Löfelmann M, Gargulák M, Dočekalová M, Ruttkay-Nedecký B, Suchý P, Kepinská M, Kizek R.
    • Klin Onkol. 2017 Spring;30(Supplementum1):177-179.
    • HDAC10 as a potential therapeutic target in ovarian cancer.
    • Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, Parvin JD.
    • Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
    • Prophylactic window therapy with the clinical PARP inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    • van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.
    • J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.
    • The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
    • Jelinic P, Eccles LA, Tseng J, Cybulska P, Wielgos M, Powell SN, Levine DA.
    • Oncotarget. 2017 Feb 21;8(8):13792-13804. doi: 10.18632/oncotarget.14637.
    • CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
    • Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S.
    • Nat Commun. 2017 Feb 17;8:14432. doi: 10.1038/ncomms14432.
    • Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.
    • Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti Á, Krzystanek M, Ribli D, Szalai-Gindl JM, Csabai I, Szallasi Z, Swanton C, Richardson AL, Szüts D.
    • Oncogene. 2017 Feb 9;36(6):746-755. doi: 10.1038/onc.2016.243. Epub 2016 Jul 25.
    • PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    • Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X.
    • Sci Rep. 2017 Feb 8;7:42319. doi: 10.1038/srep42319.
    • BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    • Sinha A, Paul BT, Sullivan LM, Sims H, Bastawisy AE, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.
    • Oncotarget. 2017 Feb 7;8(6):10114-10135. doi: 10.18632/oncotarget.14357.
    • Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    • Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.
    • Cancer Lett. 2017 Feb 1;386:131-140. doi: 10.1016/j.canlet.2016.11.021. Epub 2016 Nov 25.
    • PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.
    • Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH.
    • Cancer Biother Radiopharm. 2017 Feb;32(1):9-15. doi: 10.1089/cbr.2016.2133. Epub 2017 Jan 24.
    • Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    • Bayer CM, Beckmann MW, Fasching PA.
    • Curr Opin Obstet Gynecol. 2017 Feb;29(1):4-11. doi: 10.1097/GCO.0000000000000333.
    • Review
    • A novel hysteroscopic approach for ovarian cancer screening/early diagnosis.
    • Gizzo S, Noventa M, Quaranta M, Vitagliano A, Saccardi C, Litta P, Antona D.
    • Oncol Lett. 2017 Feb;13(2):549-553. doi: 10.3892/ol.2016.5493. Epub 2016 Dec 14.
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
    • Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.
    • Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.
    • Chemopreventive effects of ROS targeting in a murine model of BRCA1-deficient breast cancer.
    • Li M, Yu X, Chen Q.
    • Cancer Res. 2017 Jan 15;77(2):448-458. doi: 10.1158/0008-5472.CAN-16-2350. Epub 2016 Nov 4.
    • A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
    • George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.
    • JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.
    • Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    • Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.
    • BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
    • Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    • Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.
    • Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.
    • Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    • Kotsopoulos J, Singer C, Narod SA.
    • Breast Cancer Res Treat. 2017 Jan;161(1):11-16. doi: 10.1007/s10549-016-4029-z. Epub 2016 Oct 25.
    • Review
    • Differential expression of parental alleles of BRCA1 in human preimplantation embryos.
    • Tulay P, Doshi A, Serhal P, SenGupta SB.
    • Eur J Hum Genet. 2017 Jan;25(1):37-42. doi: 10.1038/ejhg.2016.121. Epub 2016 Sep 28.
    • Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
    • Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.
    • J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21.
    • MicroRNA in breast cancer: The association with BRCA1/2.
    • Nina P, Radoslav D, Vladan B, Milan O, Esma IR.
    • Cancer Biomark. 2017;19(2):119-128. doi: 10.3233/CBM-160319.
    • Review
    • Fork Protection and Therapy Resistance in Hereditary Breast Cancer.
    • Cantor SB, Calvo JA.
    • Cold Spring Harb Symp Quant Biol. 2017;82:339-348. doi: 10.1101/sqb.2017.82.034413. Epub 2018 Feb 22.
    • Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays.
    • Na Z, Pan S, Uttamchandani M, Yao SQ.
    • Methods Mol Biol. 2017;1518:139-156.
    • Pitaya Extracts Induce Growth Inhibition and Proapoptotic Effects on Human Cell Lines of Breast Cancer via Downregulation of Estrogen Receptor Gene Expression.
    • Guimarães DAB, De Castro DDSB, de Oliveira FL, Nogueira EM, da Silva MAM, Teodoro AJ.
    • Oxid Med Cell Longev. 2017;2017:7865073. doi: 10.1155/2017/7865073. Epub 2017 Jul 6.
    • Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    • Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.
    • PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • Yeast cells reveal the misfolding and the cellular mislocalisation of the human BRCA1 protein.
    • Thouvenot P, Fourrière L, Dardillac E, Ben Yamin B, Lescure A, Lejour V, Heiligenstein X, Boulé JB, Romao M, Raposo-Benedetti G, Lopez BS, Nicolas A, Millot GA.
    • J Cell Sci. 2016 Dec 1;129(23):4366-4378. Epub 2016 Oct 17.

    "In This Issue":

    Yeast cells detect human BRCA1 misfolding.

    • Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
    • Anderson RC, Makvandi M, Xu K, Lieberman BP, Zeng C, Pryma DA, Mach RH.
    • Nucl Med Biol. 2016 Dec;43(12):752-758. doi: 10.1016/j.nucmedbio.2016.08.007. Epub 2016 Aug 12.
    • The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    • Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X.
    • Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. eCollection 2016.
    • Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN.
    • Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, Uddin I, Wylie H, Strydom A, Lunter G, Rahman N.
    • Wellcome Open Res. 2016 Nov 25;1:20. doi: 10.12688/wellcomeopenres.10069.1.
    • CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    • Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.
    • Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
    • Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    • Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y.
    • Oncotarget. 2016 Nov 22;7(47):76534-76550. doi: 10.18632/oncotarget.12266.
    • Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
    • Tang Q, Cheng J, Cao X, Surowy H, Burwinkel B.
    • Clin Epigenetics. 2016 Nov 14;8:115. eCollection 2016.
    • LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
    • Wang YS, Chen J, Cui F, Wang H, Wang S, Hang W, Zeng Q, Quan CS, Zhai YX, Wang JW, Shen XF, Jian YP, Zhao RX, Werle KD, Cui R, Liang J, Li YL, Xu ZX.
    • Oncotarget. 2016 Nov 8;7(45):73389-73401. doi: 10.18632/oncotarget.12334.
    • The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
    • Bhute VJ, Ma Y, Bao X, Palecek SP.
    • Sci Rep. 2016 Nov 4;6:36061. doi: 10.1038/srep36061.
    • Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.
    • Dunkel Y, Diao K, Aznar N, Swanson L, Liu L, Zhu W, Mi X, Ghosh P.
    • FASEB J. 2016 Nov;30(11):3702-3713. Epub 2016 Jul 20.
    • In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis.
    • Deniz M, Kaufmann J, Stahl A, Gundelach T, Janni W, Hoffmann I, Keimling M, Hampp S, Ihle M, Wiesmüller L.
    • FASEB J. 2016 Nov;30(11):3786-3799. Epub 2016 Aug 5.
    • Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
    • Kargaran PK, Yasaei H, Anjomani-Virmouni S, Mangiapane G, Slijepcevic P.
    • Genes Chromosomes Cancer. 2016 Nov;55(11):864-76. doi: 10.1002/gcc.22386. Epub 2016 Jul 26.
    • In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    • AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.
    • Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.
    • Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    • Morse CB, Norquist BM, Harrell MI, Agnew KJ, Gray HJ, Urban RR, Garcia RL, Goff BA, Swisher EM.
    • Gynecol Oncol. 2016 Nov;143(2):389-392. doi: 10.1016/j.ygyno.2016.08.324. Epub 2016 Aug 27.
    • RANKL/RANK: from bone loss to the prevention of breast cancer.
    • Sigl V, Jones LP, Penninger JM.
    • Open Biol. 2016 Nov;6(11). pii: 160230.
    • Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation.
    • Kass EM, Lim PX, Helgadottir HR, Moynahan ME, Jasin M.
    • Nat Commun. 2016 Oct 25;7:13241. doi: 10.1038/ncomms13241.
    • Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
    • Lodovichi S, Vitello M, Cervelli T, Galli A.
    • Cell Cycle. 2016 Oct 17;15(20):2723-31. doi: 10.1080/15384101.2016.1215389. Epub 2016 Aug 2.
    • The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
    • Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.
    • Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.
    • The current status of PARP inhibitors in ovarian cancer.
    • McLachlan J, George A, Banerjee S.
    • Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
    • Review
    • Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    • Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV.
    • Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.
    • Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
    • Lo PK, Zhang Y, Wolfson B, Gernapudi R, Yao Y, Duru N, Zhou Q.
    • Oncotarget. 2016 Oct 4;7(40):65067-65089. doi: 10.18632/oncotarget.11364.
    • RING-less BRCA1 Induces PARP Inhibitor and Platinum Resistance.
    • [No authors listed]
    • Cancer Discov. 2016 Oct;6(10):OF6. Epub 2016 Aug 12.
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • BRCA2 functions: from DNA repair to replication fork stabilization.
    • Fradet-Turcotte A, Sitz J, Grapton D, Orthwein A.
    • Endocr Relat Cancer. 2016 Oct;23(10):T1-T17. Epub 2016 Aug 16.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Defects in homologous recombination repair behind the human diseases: FA and HBOC.
    • Katsuki Y, Takata M.
    • Endocr Relat Cancer. 2016 Oct;23(10):T19-T37. Epub 2016 Aug 22.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    • Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D.
    • Gynecol Oncol. 2016 Oct;143(1):143-51. doi: 10.1016/j.ygyno.2016.07.088. Epub 2016 Jul 19.
    • Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
    • Oommen D, Dodd NJ, Yiannakis D, Moyeed R, Jha AN.
    • Mutat Res. 2016 Oct;809:43-49. doi: 10.1016/j.mrgentox.2016.09.003. Epub 2016 Sep 4.
    • Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
    • Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF.
    • Radiat Res. 2016 Oct;186(4):327-332. Epub 2016 Sep 2.
    • Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
    • Warmoes M, Lam SW, der Groep PV, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.
    • Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.
    • A second DNA binding site in human BRCA2 promotes homologous recombination.
    • von Nicolai C, Ehlén Å, Martin C, Zhang X, Carreira A.
    • Nat Commun. 2016 Sep 15;7:12813. doi: 10.1038/ncomms12813.
    • 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    • Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B.
    • BMC Cancer. 2016 Sep 9;16(1):725. doi: 10.1186/s12885-016-2754-7.
    • Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study.
    • Kim SJ, Zuchniak A, Sohn KJ, Lubinski J, Demsky R, Eisen A, Akbari MR, Kim YI, Narod SA, Kotsopoulos J.
    • Am J Clin Nutr. 2016 Sep;104(3):671-7. doi: 10.3945/ajcn.116.133470. Epub 2016 Jul 27.
    • PTIP Loss Protects BRCA-Deficient Cells from DNA Damage and Cell Death.
    • [No authors listed]
    • Cancer Discov. 2016 Sep;6(9):944. doi: 10.1158/2159-8290.CD-RW2016-142. Epub 2016 Jul 29.
    • Research Watch
    • A Review of Whole Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery.
    • Chandler MR, Bilgili EP, Merner ND.
    • Hum Mutat. 2016 Sep;37(9):835-46. doi: 10.1002/humu.23017. Epub 2016 Jun 27.
    • Review
    • Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b.
    • Mogilyansky E, Clark P, Quann K, Zhou H, Londin E, Jing Y, Rigoutsos I.
    • Front Genet. 2016 Aug 31;7:143. doi: 10.3389/fgene.2016.00143. eCollection 2016.
    • NCI Launches Large Study of Breast Cancer Genetics in Black Women
    • Jennifer Abbasi
    • JAMA. 2016 Aug 23;316(8):808. doi:10.1001/jama.2016.11180.
    • News
    • Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
    • Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.
    • Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.
    • Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: Evidence for metformin-based "starvation" strategies in BRCA1 carriers.
    • Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA.
    • Oncotarget. 2016 Aug 16;7(33):52974-52992. doi: 10.18632/oncotarget.9732.
    • Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.
    • Hartford SA, Chittela R, Ding X, Vyas A, Martin B, Burkett S, Haines DC, Southon E, Tessarollo L, Sharan SK.
    • PLoS Genet. 2016 Aug 4;12(8):e1006236. doi: 10.1371/journal.pgen.1006236. eCollection 2016.
    • BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    • Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.
    • J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    • Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.
    • J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25.

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    • Alshareeda AT, Negm OH, Aleskandarany MA, Green AR, Nolan C, TigHhe PJ, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2016 Aug;159(1):41-53. doi: 10.1007/s10549-016-3915-8. Epub 2016 Jul 27.
    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BS, Rakha EA, Nolan C, Ellis IO, Green AR.
    • Malays J Pathol. 2016 Aug;38(2):83-92.
    • RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    • Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ.
    • Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.
    • FANCD2 limits replication stress and genome instability in cells lacking BRCA2.
    • Michl J, Zimmer J, Buffa FM, McDermott U, Tarsounas M.
    • Nat Struct Mol Biol. 2016 Aug;23(8):755-7. doi: 10.1038/nsmb.3252. Epub 2016 Jun 20.

    Editorial / Commentary

    A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells.

    • MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    • Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
    • BMC Cancer. 2016 Jul 27;16(1):550. doi: 10.1186/s12885-016-2598-1.
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw A, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC.
    • PLoS One. 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801.
    • Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    • Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L, Cross SS, Cox A
    • PLoS One. 2016 Jul 27;11(7):e0160174. doi: 10.1371/journal.pone.0160174.
    • Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.
    • Hengel SR, Malacaria E, Folly da Silva Constantino L, Bain FE, Diaz A, Koch BG, Yu L, Wu M, Pichierri P, Spies MA, Spies M.
    • Elife. 2016 Jul 19;5. pii: e14740. doi: 10.7554/eLife.14740.
    • Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
    • Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.
    • Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.
    • Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.
    • Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA.
    • Cell Stem Cell. 2016 Jul 7;19(1):52-65. doi: 10.1016/j.stem.2016.05.003. Epub 2016 Jun 9.
    • NIH launches largest-ever study of breast cancer genetics in black women.
    • [No author given]
    • NIH. 2016 Jul 6.
    • Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    • Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Jóźwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.
    • J Natl Cancer Inst. 2016 Jul 5;108(11). pii: djw148. Print 2016 Nov.
    • RANKL/RANK control Brca1 mutation-driven mammary tumors.
    • Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.
    • Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

    Prevention of breast cancer by RANKL/RANK blockade.

    • BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.
    • Gu Y, Helenius M, Väänänen K, Bulanova D, Saarela J, Sokolenko A, Martens J, Imyanitov E, Kuznetsov S.
    • Sci Rep. 2016 Jun 17;6:28217. doi: 10.1038/srep28217.
    • Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
    • Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S.
    • Cancers (Basel). 2016 Jun 16;8(6). pii: E56. doi: 10.3390/cancers8060056.
    • FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.
    • Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea AD, Ceccaldi R.
    • Cell Rep. 2016 Jun 14;15(11):2488-99. doi: 10.1016/j.celrep.2016.05.031. Epub 2016 Jun 2.
    • An In Vivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter.
    • Huo Y, Su T, Cai Q, Macara IG.
    • Cell Rep. 2016 Jun 7;15(10):2089-96. doi: 10.1016/j.celrep.2016.05.011. Epub 2016 May 26.
    • Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    • Chen KH, Walker AM.
    • Cancer Lett. 2016 Jun 1;375(2):293-302. doi: 10.1016/j.canlet.2016.03.007. Epub 2016 Mar 9.
    • Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    • Somasundaram V, Hemalatha SK, Pal K, Sinha S, Nair AS, Mukhopadhyay D, Srinivas P.
    • BMC Cancer. 2016 May 26;16(1):336. doi: 10.1186/s12885-016-2372-4.
    • Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
    • Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV.
    • Nucleic Acids Res. 2016 May 19;44(9):4189-99. doi: 10.1093/nar/gkw087. Epub 2016 Feb 11.
    • BRCA2 minor transcript lacking exons4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.
    • Thirthagiri E, Klarmann KD, Shukla AK, Southon E, Biswas K, Martin BK, North SL, Magidson V, Burkett S, Haines DC, Noer K, Matthai R, Tessarollo L, Loncarek J, Keller JR, Sharan SK.
    • Hum Mol Genet. 2016 May 15;25(10):1934-1945. Epub 2016 Feb 26.
    • Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients.
    • Hamam D, Abdouh M, Gao ZH, Arena V, Arena M, Arena GO.
    • J Exp Clin Cancer Res. 2016 May 14;35(1):80. doi: 10.1186/s13046-016-0360-9.
    • The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
    • Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N.
    • Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186.

    News: Preventing Drug Resistance in Patients With Germline BRCA1 Mutations. (OncoTherapy Network)

    • Artificial neural network-based exploration of gene-nutrient interactions in folate and xenobiotic metabolic pathways that modulate susceptibility to breast cancer.
    • Naushad SM, Janaki Ramaiah M, Pavithrakumari M, Jayapriya J, Hussain T, Alrokayan SA, Gottumukkala SR, Digumarti R, Kutala VK.
    • Gene. 2016 Apr 15;580(2):159-68. doi: 10.1016/j.gene.2016.01.023. Epub 2016 Jan 16.
    • MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    • Matamala N, Vargas MT, González-Cámpora R, Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras A, Miñambres R, Martínez-Delgado B, Benítez J.
    • Oncotarget. 2016 Apr 12;7(15):20068-79. doi: 10.18632/oncotarget.7705.
    • Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
    • Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.
    • Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.
    • miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
    • Crippa E, Folini M, Pennati M, Zaffaroni N, Pierotti MA, Gariboldi M.
    • Oncotarget. 2016 Apr 5;7(14):18594-18604. doi: 10.18632/oncotarget.7617.
    • Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine.
    • Nilov DK, Tararov VI, Kulikov AV, Zakharenko AL, Gushchina IV, Mikhailov SN, Lavrik OI, Švedas VK.
    • Acta Naturae. 2016 Apr-Jun;8(2):108-15.
    • Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model.
    • Chapa J, An G, Kulkarni SA.
    • PLoS One. 2016 Mar 29;11(3):e0152298. doi: 10.1371/journal.pone.0152298. eCollection 2016.
    • Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    • Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H.
    • Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549.
    • Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome.
    • Menendez JA, Folguera-Blasco N, Cuyàs E, Fernández-Arroyo S, Joven J, Alarcón T.
    • Oncotarget. 2016 Mar 15;7(11):11959-71. doi: 10.18632/oncotarget.7867.
    • Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility.
    • Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH.
    • Mol Syst Biol. 2016 Mar 10;12(3):860. doi: 10.15252/msb.20156506.
    • Genetic Test Firm to Make Customers’ Data Publicly Available.
    • Andrew Pollack.
    • New York Times. Business Day. 2016 Mar 8.
    • Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability.
    • Trego KS, Groesser T, Davalos AR, Parplys AC, Zhao W, Nelson MR, Hlaing A, Shih B, Rydberg B, Pluth JM, Tsai MS, Hoeijmakers JH, Sung P, Wiese C, Campisi J, Cooper PK.
    • Mol Cell. 2016 Feb 18;61(4):535-46. doi: 10.1016/j.molcel.2015.12.026. Epub 2016 Jan 28.
    • BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
    • Oommen D, Yiannakis D, Jha AN.
    • Mutat Res. 2016 Feb-Mar;784-785:8-15. doi: 10.1016/j.mrfmmm.2015.11.002. Epub 2015 Nov 28.
    • Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    • Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    • Nat Med. 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032. Epub 2016 Jan 18.
    • Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
    • Vasanthakumar A, Arnovitz S, Marquez R, Lepore J, Rafidi G, Asom A, Weatherly M, Davis EM, Neistadt B, Duszynski R, Vardiman JW, Le Beau MM, Godley LA, Churpek JE.
    • Blood. 2016 Jan 21;127(3):310-3. doi: 10.1182/blood-2015-03-635599. Epub 2015 Dec 7.
    • It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research.
    • Perets R, Drapkin R.
    • Cancer Res. 2016 Jan 1;76(1):10-7. doi: 10.1158/0008-5472.CAN-15-1382. Epub 2015 Dec 15.
    • Review
    • Regulators of genetic risk of breast cancer identified by integrative network analysis.
    • Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E, Tilley WD, Markowetz F, Ponder BA, Meyer KB.
    • Nat Genet. 2016 Jan;48(1):12-21. doi: 10.1038/ng.3458. Epub 2015 Nov 30.
    • DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice.
    • Suberbielle E, Djukic B, Evans M, Kim DH, Taneja P, Wang X, Finucane M, Knox J, Ho K, Devidze N, Masliah E, Mucke L.
    • Nat Commun. 2015 Nov 30;6:8897. doi: 10.1038/ncomms9897.
    • Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
    • Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.
    • Chem Biol. 2015 Nov 19;22(11):1491-504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.
    • Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response.
    • Zhang F, Shi J, Bian C, Yu X.
    • Cell Rep. 2015 Oct 27;13(4):678-689. doi: 10.1016/j.celrep.2015.09.040. Epub 2015 Oct 17.
    • Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent.
    • Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L.
    • PLoS One. 2015 Oct 21;10(10):e0139013. doi: 10.1371/journal.pone.0139013. eCollection 2015.
    • Mitochondrial Genetics Regulate Breast Cancer Tumorigenicity and Metastatic Potential.
    • Feeley KP, Bray AW, Westbrook DG, Johnson LW, Kesterson RA, Ballinger SW, Welch DR.
    • Cancer Res. 2015 Oct 15;75(20):4429-36. doi: 10.1158/0008-5472.CAN-15-0074.
    • Mitochondrial DNA Polymerase POLG1 Disease Mutations and Germline Variants Promote Tumorigenic Properties.
    • Singh B, Owens KM, Bajpai P, Desouki MM, Srinivasasainagendra V, Tiwari HK, Singh KK.
    • PLoS One. 2015 Oct 15;10(10):e0139846. doi: 10.1371/journal.pone.0139846. eCollection 2015.
    • MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
    • Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, Collavoli A, Falaschi E, Rossetti E, Aretini P, Cervelli T, Galli A, Caligo MA.
    • Eur J Med Genet. 2015 Oct;58(10):531-9. doi: 10.1016/j.ejmg.2015.09.005. Epub 2015 Sep 14.
    • YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
    • Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM.
    • Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26.
    • Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    • Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.
    • Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
    • A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
    • Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L.
    • EBioMedicine. 2015 Sep 9;2(10):1318-30. doi: 10.1016/j.ebiom.2015.08.034. eCollection 2015.

    Comment

    A Quest for Better Mouse Models of Breast and Ovarian Cancers.

    • Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
    • Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC.
    • EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015.

    Commentary

    RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.

    • Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
    • Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.
    • Genes Cancer. 2015 Sep;6(9-10):378-398.
    • Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.
    • Nakshatri H, Anjanappa M, Bhat-Nakshatri P.
    • Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.
    • The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
    • Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS.
    • Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6. doi: 10.1016/j.bbrc.2015.05.083. Epub 2015 Jun 3.
    • BRCA1: Beyond double-strand break repair.
    • Alli E, Ford JM.
    • DNA Repair (Amst). 2015 Aug;32:165-71. doi: 10.1016/j.dnarep.2015.04.028. Epub 2015 May 1.
    • Review
    • Nitric Oxide: Genomic Instability And Synthetic Lethality.
    • Yakovlev VA.
    • Redox Biol. 2015 Aug;5:414. doi: 10.1016/j.redox.2015.09.013. Epub 2015 Dec 30.
    • Deciphering the BRCA1 Tumor Suppressor Network.
    • Jiang Q, Greenberg RA.
    • J Biol Chem. 2015 Jul 17;290(29):17724-32. doi: 10.1074/jbc.R115.667931. Epub 2015 Jun 5.
    • Review
    • Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
    • Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.
    • Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8409-14. doi: 10.1073/pnas.1500223112. Epub 2015 Jun 22.
    • FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis.
    • Huang YL, Chou WC, Hsiung CN, Hu LY, Chu HW, Shen CY.
    • Hum Mol Genet. 2015 Jun 15;24(12):3506-17. doi: 10.1093/hmg/ddv102. Epub 2015 Mar 18.
    • Mislocalization of BRCA1-complex due to ABRAXAS Arg361Gln mutation.
    • Vikrant, Kumar R, Siddiqui Q, Singh N, Waghmare SK, Varma AK.
    • J Biomol Struct Dyn. 2015 Jun;33(6):1291-301. doi: 10.1080/07391102.2014.945484. Epub 2014 Aug 8.
    • Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    • Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.
    • Oncotarget. 2015 May 10;6(13):11575-84.
    • Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    • Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.
    • Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.
    • Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins.
    • Prakash R, Zhang Y, Feng W, Jasin M.
    • Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4). pii: a016600. doi: 10.1101/cshperspect.a016600.
    • Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    • Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.
    • PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.
    • BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
    • Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.
    • Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.
    • BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    • Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.
    • Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.
    • BRCA1, a 'complex' protein involved in the maintenance of genomic stability.
    • Savage KI, Harkin DP.
    • FEBS J. 2015 Feb;282(4):630-46. doi: 10.1111/febs.13150. Epub 2014 Dec 2.
    • It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
    • Carlucci A, D'Angiolella V.
    • Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
    • MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
    • Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.
    • Oncotarget. 2015 Jan 1;6(1):471-83.
    • Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
    • Somyajit K, Mishra A, Jameei A, Nagaraju G.
    • Carcinogenesis. 2015 Jan;36(1):13-24. doi: 10.1093/carcin/bgu211. Epub 2014 Oct 7.
    • BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.
    • Woolery KT, Mohamed M, Linger RJ, Dobrinski KP, Roman J, Kruk PA.
    • Biomed Res Int. 2015;2015:652017. doi: 10.1155/2015/652017. Epub 2015 Aug 19.
    • Orchestration of DSB repair: a novel BRCA2 connection.
    • Gatti L, Perego P.
    • Cell Cycle. 2015;14(14):2195-6. doi: 10.1080/15384101.2015.1056614. Epub 2015 Jun 1.

    BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.

    • Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
    • Desai A, Xu J, Aysola K, Akinbobuyi O, White M, Reddy VE, Okoli J, Clark C, Partridge EE, Childs E, Beech DJ, Rice MV, Reddy E, Rao VN.
    • J Gynecol Res. 2015;1(1). pii: 103. Epub 2015 Apr 24.
    • Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    • Niskakoski A, Kaur S, Staff S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P.
    • Epigenetics. 2014 Dec 2;9(12):1577-87. doi: 10.4161/15592294.2014.983374.
    • Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.
    • Chene G, Cayre A, Raoelfils I, Lagarde N, Dauplat J, Penault-Llorca F.
    • Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:89-95. doi: 10.1016/j.ejogrb.2014.10.003. Epub 2014 Oct 14.
    • TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes.
    • Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.
    • Mol Cancer Res. 2014 Nov;12(11):1597-609. doi: 10.1158/1541-7786.MCR-14-0201. Epub 2014 Aug 7.
    • A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.
    • Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Yang Q.
    • Sci Rep. 2014 Oct 17;4:6666. doi: 10.1038/srep06666.
    • Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    • García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    • Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.
    • BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.
    • Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.
    • Br J Cancer. 2014 Sep 23;111(7):1269-1274. doi: 10.1038/bjc.2014.391. Epub 2014 Jul 15.
    • Synergistic therapeutic effect of cisplatin and phosphatidylinositol 3-kinase (PI3K) inhibitors in cancer growth and metastasis of Brca1 mutant tumors.
    • Vassilopoulos A, Xiao C, Chisholm C, Chen W, Xu X, Lahusen TJ, Bewley C, Deng CX.
    • J Biol Chem. 2014 Aug 29;289(35):24202-14. doi: 10.1074/jbc.M114.567552. Epub 2014 Jul 8.
    • Male Fertility Defect Associated with Disrupted BRCA1-PALB2 Interaction in Mice.
    • Simhadri S, Peterson S, Patel DS, Huo Y, Cai H, Bowman-Colin C, Miller S, Ludwig T, Ganesan S, Bhaumik M, Bunting SF, Jasin M, Xia B.
    • J Biol Chem. 2014 Aug 29;289(35):24617-29. doi: 10.1074/jbc.M114.566141. Epub 2014 Jul 11.
    • Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.
    • Colombo M, Blok MJ, Whiley P, Santamariña M, Gutiérrez-Enríquez S, Romero A, Garre P, Becker A, Smith LD, De Vecchi G, Brandão RD, Tserpelis D, Brown M, Blanco A, Bonache S, Menéndez M, Houdayer C, Foglia C, Fackenthal JD, Baralle D, Wappenschmidt B; kConFaB Investigators, Díaz-Rubio E, Caldés T, Walker L, Díez O, Vega A, Spurdle AB, Radice P, De La Hoya M.
    • Hum Mol Genet. 2014 Jul 15;23(14):3666-80. doi: 10.1093/hmg/ddu075. Epub 2014 Feb 25.
    • Rapid evolution of BRCA1 and BRCA2 in humans and other primates.
    • Lou DI, McBee RM, Le UQ, Stone AC, Wilkerson GK, Demogines AM, Sawyer SL.
    • BMC Evol Biol. 2014 Jul 11;14:155. doi: 10.1186/1471-2148-14-155.
    • Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line.
    • Schröder-Heurich B, Bogdanova N, Wieland B, Xie X, Noskowicz M, Park-Simon TW, Hillemanns P, Christiansen H, Dörk T.
    • BMC Cancer. 2014 Jun 13;14:434. doi: 10.1186/1471-2407-14-434.
    • BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability.
    • Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP.
    • Cancer Res. 2014 May 15;74(10):2773-84. doi: 10.1158/0008-5472.CAN-13-2611. Epub 2014 Mar 17.
    • BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
    • Wang L, Di LJ.
    • Int J Biol Sci. 2014 May 14;10(5):566-75. doi: 10.7150/ijbs.8579. eCollection 2014.
    • Stakeholder consultation insights on the future of genomics at the clinical-public health interface.
    • Modell SM, Kardia SL2, Citrin T3.
    • Transl Res. 2014 May;163(5):466-77. doi: 10.1016/j.trsl.2013.12.007. Epub 2013 Dec 25.
    • Review
    • BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
    • Tang MK, Kwong A, Tam KF, Cheung AN, Ngan HY, Xia W, Wong A.
    • Cancer Lett. 2014 Apr 28;346(1):139-47. doi: 10.1016/j.canlet.2013.12.026. Epub 2013 Dec 28.
    • BRCA1 and Oxidative Stress.
    • Yi YW, Kang HJ, Bae I.
    • Cancers (Basel). 2014 Apr 3;6(2):771-95. doi: 10.3390/cancers6020771.
    • Role of BRCA1 in brain development.
    • Pao GM, Zhu Q, Perez-Garcia CG, Chou SJ, Suh H, Gage FH, O'Leary DD, Verma IM.
    • Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1240-8. doi: 10.1073/pnas.1400783111. Epub 2014 Mar 17.
    • Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2.
    • Venkitaraman AR.
    • Science. 2014 Mar 28;343(6178):1470-5. doi: 10.1126/science.1252230.
    • Editorial / Commentary
    • Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer.
    • Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.
    • Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.
    • Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
    • Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.
    • Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.

    Comment:

    Tissue-specific tumor suppression by BRCA1.

    • PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer.
    • Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.
    • Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.
    • Epigenetic repression of phosphatidylethanolamine, N-methyltransferase (PEMT) in BRCA1-mutated breast cancer.
    • Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Cao C, Li CY, Yang Q.
    • Oncotarget. 2014 Mar 15;5(5):1315-25.
    • Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation.
    • Cassidy LD, Liau SS, Venkitaraman AR.
    • Mol Oncol. 2014 Mar;8(2):161-8. doi: 10.1016/j.molonc.2013.10.005. Epub 2013 Nov 6.
    • HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
    • Wang X, Lu G, Li L, Yi J, Yan K, Wang Y, Zhu B, Kuang J, Lin M, Zhang S, Shao G.
    • Biochem Biophys Res Commun. 2014 Feb 21;444(4):549-54. doi: 10.1016/j.bbrc.2014.01.075. Epub 2014 Jan 25.
    • Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    • De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.
    • Cell Death Dis. 2014 Feb 20;5:e1076. doi: 10.1038/cddis.2014.30.
    • Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation.
    • Li D, Bi FF, Cao JM, Cao C, Liu B, Yang Q.
    • Mol Cancer. 2014 Feb 6;13:26. doi: 10.1186/1476-4598-13-26.
    • Retraction: BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220.
    • [No authors listed]
    • Oncogene. 2014 Feb 6;33(6):804. doi: 10.1038/onc.2013.526.
    • Compensatory Functions and Interdependency of the DNA-Binding Domain of BRCA2 with the BRCA1-PALB2-BRCA2 Complex.
    • Al Abo M, Dejsuphong D, Hirota K, Yonetani Y, Yamazoe M, Kurumizaka H, Takeda S.
    • Cancer Res. 2014 Feb 1;74(3):797-807. doi: 10.1158/0008-5472.CAN-13-1443. Epub 2013 Nov 27.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: BRCA2 and PALB2 mutation

    • Clinical significance of CYLD downregulation in breast cancer.
    • Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.
    • Breast Cancer Res Treat. 2014 Feb;143(3):447-57. doi: 10.1007/s10549-013-2824-3. Epub 2014 Jan 8.
    • Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
    • Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, Greene MH, Gail MH.
    • Breast Cancer Res Treat. 2014 Feb;143(3):517-29. doi: 10.1007/s10549-013-2821-6. Epub 2014 Jan 18.

    Letter, Comment:

    Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

    Letter, Comment:

    Concerns about methods for determination of estrogens in body fluids.

    • Generation of iPSCs from Genetically Corrected Brca2 Hypomorphic Cells: Implications in Cell Reprogramming and Stem Cell Therapy.
    • Navarro S, Moleiro V, Molina-Estevez FJ, Lozano ML, Chinchon R, Almarza E, Quintana-Bustamante O, Mostoslavsky G, Maetzig T, Galla M, Heinz N, Schiedlmeier B, Torres Y, Modlich U, Samper E, Río P, Segovia JC, Raya A, Güenechea G, Izpisua-Belmonte JC, Bueren JA.
    • Stem Cells. 2014 Feb;32(2):436-46. doi: 10.1002/stem.1586.
    • DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer.
    • Pinto R, De Summa S, Pilato B, Tommasi S.
    • Curr Mol Med. 2014 Jan;14(1):45-57.
    • Review
    • BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
    • Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Wang XX.
    • Cell Cycle. 2014;13(16):2564-71. doi: 10.4161/15384101.2015.942208.
    • Epigenetic mechanisms of breast cancer: an update of the current knowledge.
    • Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, Bignon YJ, Bernard-Gallon D.
    • Epigenomics. 2014;6(6):651-64. doi: 10.2217/epi.14.59.
    • Review
    • Network-based analysis of omics with multi-objective optimization.
    • Mosca E, Milanesi L.
    • Mol Biosyst. 2013 Dec 29;9(12):2971-80. doi: 10.1039/c3mb70327d. Epub 2013 Oct 14.
    • BRCA2: one small step for DNA repair, one giant protein purified.
    • Jensen RB.
    • Yale J Biol Med. 2013 Dec 13;86(4):479-89.
    • Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
    • Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
    • Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

    Research news:

    Ovarian cancer: A better mimic.

    • Refining the role of BRCA1 in combating oxidative stress.
    • Marks JR.
    • Breast Cancer Res. 2013 Dec 5;15(6):320. doi: 10.1186/bcr3583.
    • Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.
    • Pal T, Vadaparampil S, Kim J, Xu Y, Friedman S, Narod SA, Metcalfe K.
    • Fam Cancer. 2013 Dec;12(4):615-9. doi: 10.1007/s10689-013-9624-0.
    • Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    • Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD.
    • Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94. doi: 10.1073/pnas.1314302110. Epub 2013 Nov 11.
    • Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
    • Barcellos-Hoff MH, Kleinberg DL.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii8-viii12. doi: 10.1093/annonc/mdt305.
    • BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
    • Singh KK, Shukla PC, Quan A, Al-Omran M, Lovren F, Pan Y, Brezden-Masley C, Ingram AJ, Stanford WL, Teoh H, Verma S.
    • J Thorac Cardiovasc Surg. 2013 Oct;146(4):949-960.e4. doi: 10.1016/j.jtcvs.2012.12.064. Epub 2013 Feb 14.
    • A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.
    • Jeyasekharan AD, Liu Y, Hattori H, Pisupati V, Jonsdottir AB, Rajendra E, Lee M, Sundaramoorthy E, Schlachter S, Kaminski CF, Ofir-Rosenfeld Y, Sato K, Savill J, Ayoub N, Venkitaraman AR.
    • Nat Struct Mol Biol. 2013 Oct;20(10):1191-8. doi: 10.1038/nsmb.2666. Epub 2013 Sep 8.
    • BRCA1 and p53 regulate critical prostate cancer pathways.
    • De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.
    • Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    • Lok BH, Carley AC, Tchang B, Powell SN.
    • Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.
    • Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
    • Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.
    • Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.
    • COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration.
    • COMPLEXO, Southey MC, Park DJ, Nguyen-Dumont T, Campbell I, Thompson E, Trainer AH, Chenevix-Trench G, Simard J, Dumont M, Soucy P, Thomassen M, Jønson L, Pedersen IS, Hansen TV, Nevanlinna H, Khan S, Sinilnikova O, Mazoyer S, Lesueur F, Damiola F, Schmutzler R, Meindl A, Hahnen E, Dufault MR, Chris Chan T, Kwong A, Barkardóttir R, Radice P, Peterlongo P, Devilee P, Hilbers F, Benitez J, Kvist A, Törngren T, Easton D, Hunter D, Lindstrom S, Kraft P, Zheng W, Gao YT, Long J, Ramus S, Feng BJ, Weitzel JN, Nathanson K, Offit K, Joseph V, Robson M, Schrader K, Wang S, Kim YC, Lynch H, Snyder C, Tavtigian S, Neuhausen S, Couch FJ, Goldgar DE.
    • Breast Cancer Res. 2013 Jun 21;15(3):402. doi: 10.1186/bcr3434.
    • BRCA1 in the DNA damage response and at telomeres.
    • Rosen EM.
    • Front Genet. 2013 Jun 21;4:85. doi: 10.3389/fgene.2013.00085. eCollection 2013.
    • BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
    • Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND.
    • PLoS One. 2013 Jun 21;8(6):e67313. Print 2013.
    • From integrative genomics to therapeutic targets.
    • Natrajan R, Wilkerson P.
    • Cancer Res. 2013 Jun 15;73(12):3483-8. doi: 10.1158/0008-5472.CAN-12-4717. Epub 2013 Jun 5.
    • The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
    • Nakles RE, Kallakury BV, Furth PA.
    • Am J Pathol. 2013 Jun;182(6):1976-85. doi: 10.1016/j.ajpath.2013.02.006. Epub 2013 May 8.

    Commentary:

    Anticancer activities of PPARγ in breast cancer are context-dependent.

    • Mouse models of BRCA1 and their application to breast cancer research.
    • Dine J, Deng CX.
    • Cancer Metastasis Rev. 2013 Jun;32(1-2):25-37. doi: 10.1007/s10555-012-9403-7.
    • Review
    • Identification of a non-canonical nuclear localization signal (NLS) in BRCA1 that could mediate nuclear localization of splice variants lacking the classical NLS.
    • Korlimarla A, Bhandary L, Prabhu JS, Shankar H, Sankaranarayanan H, Kumar P, Remacle J, Natarajan D, Sridhar TS.
    • Cell Mol Biol Lett. 2013 Jun;18(2):284-96. doi: 10.2478/s11658-013-0088-x. Epub 2013 May 15.
    • Does cancer start in the womb? altered mammary gland development and predisposition to breast cancer due to in utero exposure to endocrine disruptors.
    • Soto AM, Brisken C, Schaeberle C, Sonnenschein C.
    • J Mammary Gland Biol Neoplasia. 2013 Jun;18(2):199-208. doi: 10.1007/s10911-013-9293-5. Epub 2013 May 24.
    • Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    • Alvarez C, Tapia T, Cornejo V, Fernandez W, Muñoz A, Camus M, Alvarez M, Devoto L, Carvallo P.
    • Mol Carcinog. 2013 Jun;52(6):475-87. doi: 10.1002/mc.21881. Epub 2012 Feb 7.
    • BRCA2 affects the efficiency of DNA double-strand break repair in response to N-nitroso compounds with differing carcinogenic potentials.
    • Zhao WT, Wang YT, Huang ZW, Fang J.
    • Oncol Lett. 2013 Jun;5(6):1948-1954. Epub 2013 Mar 22.
    • BRCA1 mutations and luminal-basal transformation.
    • Ng T, Irshad S, Stebbing J.
    • Oncogene. 2013 May 30;32(22):2712-4. doi: 10.1038/onc.2012.379. Epub 2012 Aug 27.
    • Comment

    Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.

    • Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
    • Bai F, Smith MD, Chan HL, Pei XH.
    • Oncogene. 2013 May 30;32(22):2715-25. doi: 10.1038/onc.2012.293. Epub 2012 Jul 9.

    Comment:

    BRCA1 mutations and luminal-basal transformation.

    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    • Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.
    • Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.
    • Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
    • Li M, Yu X.
    • Cancer Cell. 2013 May 13;23(5):693-704. doi: 10.1016/j.ccr.2013.03.025.
    • A Protein Prioritization Approach Tailored for the FA/BRCA Pathway.
    • Haitjema A, Brandt BW, Ameziane N, May P, Heringa J, de Winter JP, Joenje H, Dorsman JC.
    • PLoS One. 2013 Apr 19;8(4):e62017. doi: 10.1371/journal.pone.0062017. Print 2013.
    • Opportunities for public health communication, intervention, and future research on breast cancer in younger women.
    • Buchanan N, Roland KB, Rodriguez JL, Miller JW, Fairley T.
    • J Womens Health (Larchmt). 2013 Apr;22(4):293-8. doi: 10.1089/jwh.2012.4239. Epub 2013 Mar 20.
    • A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.
    • Guinan EM, Hussey J, McGarrigle SA, Healy LA, O'Sullivan JN, Bennett K, Connolly EM.
    • BMC Cancer. 2013 Mar 21;13:138. doi: 10.1186/1471-2407-13-138.
    • The role of BRCA1 in DNA double-strand repair: past and present.
    • Caestecker KW, Van de Walle GR.
    • Exp Cell Res. 2013 Mar 10;319(5):575-87. doi: 10.1016/j.yexcr.2012.11.013. Epub 2012 Nov 29.
    • Review
    • Functional analysis-Make or break for cancer predictability.
    • Deniz M, Holzmann K, Wiesmüller L.
    • Mutat Res. 2013 Mar-Apr;743-744:132-41. doi: 10.1016/j.mrfmmm.2013.03.009. Epub 2013 Mar 28.
    • Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation.
    • Kuligina ESh, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, Gorodnova TV, Yanus GA, Togo AV, Cherdyntseva NV, Bekhtereva SA, Dixon JM, Larionov AA, Kuznetsov SG, Imyanitov EN.
    • Fam Cancer. 2013 Mar;12(1):129-32. doi: 10.1007/s10689-012-9575-x.
    • Letter
    • Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
    • Bi FF, Li D, Yang Q.
    • BMC Cancer. 2013 Feb 26;13:90. doi: 10.1186/1471-2407-13-90.
    • HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    • van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.
    • PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.
    • The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.
    • Promkan M, Dakeng S, Chakrabarty S, Bögler O, Patmasiriwat P.
    • PLoS One. 2013;8(2):e55732. doi: 10.1371/journal.pone.0055732. Epub 2013 Feb 5.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
    • Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.
    • J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.
    • Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.
    • Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.
    • VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
    • http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053070Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.
    • PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.
    • BRCA1 and Its Network of Interacting Partners.
    • Christou CM, Kyriacou K.
    • Biology (Basel). 2013 Jan 2;2(1):40-63. doi: 10.3390/biology2010040.
    • BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny.
    • Sotiropoulou PA, Karambelas AE, Debaugnies M, Candi A, Bouwman P, Moers V, Revenco T, Rocha AS, Sekiguchi K, Jonkers J, Blanpain C.
    • Genes Dev. 2013 Jan 1;27(1):39-51. doi: 10.1101/gad.206573.112. Epub 2012 Dec 27.
    • Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors.
    • Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
    • Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

    Commentary:

    Mechanisms of resistance to PARP inhibitors--three and counting.

    • BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis.
    • Teoh H, Quan A, Creighton AK, Annie Bang KW, Singh KK, Shukla PC, Gupta N, Pan Y, Lovren F, Leong-Poi H, Al-Omran M, Verma S.
    • Gene Ther. 2013 Jan;20(1):51-61. doi: 10.1038/gt.2011.214. Epub 2012 Jan 19.

Continue to Older References